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ABSTRACT 
 
Genetics of X-linked and Autosomal Recessive Hereditary Nephropathy in the Domestic 
Dog. (December 2007) 
Rebecca Jane Bell, B.S., Baylor University 
Chair of Advisory Committee: Dr. Keith E. Murphy 
 
 Although typically thought of as a beloved companion or indispensable aide, the 
domestic dog (Canis lupus familiaris) has emerged as an excellent model for the study 
of human hereditary diseases. Many hereditary diseases of the dog have nearly identical 
clinical presentations as those of the human and are, most often, caused by mutations in 
the same genes. One such disease is hereditary nephropathy; an inherited glomerular 
disease in the domestic dog that is similar to Alport syndrome of the human. Both 
diseases are caused by mutations in the type IV collagens genes, and the disease has 
nearly identical pathology and clinical presentations in the dog and human. By studying 
this disease in the dog, our laboratory hopes to increase understanding of the disease so 
that information that can be applied to both the human and the dog. Reported here is 1) 
the development of a genomic based test to determine genotypes of mixed breed dogs in 
a colony presenting with X-linked hereditary nephropathy, 2) the determination of 
patterns of X-chromosome inactivation in normal dogs and dogs that are carriers of X-
linked hereditary nephropathy, 3) the design of a synthetic COL4A5 cDNA to be used 
for gene therapy treatment of dogs with X-linked hereditary nephropathy, 4) the 
 iv
investigation of type IV collagen gene expression changes in normal dogs and those 
affected with X-linked and autosomal recessive hereditary nephropathy, and 5) the 
discovery of the mutation causative for autosomal recessive hereditary nephropathy in 
the English Cocker Spaniel. Utilization of the colony of dogs affected with X-linked 
hereditary nephropathy (for which the causative mutation was previously identified) 
allowed for comparisons of type IV collagen gene expression to English Cocker Spaniels 
with autosomal recessive hereditary nephropathy. These data were critical to 
identification of the gene harboring the causative mutation for autosomal recessive 
hereditary nephropathy. Sequencing was performed to identify the mutation. With the 
ability to test for carriers of this disease, it is our hope that breeders will use it to to 
maintain the desired traits in the ECS while simultaneously eliminating the production of 
affected offspring.            
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CHAPTER Ι 
INTRODUCTION 
The dog as a model 
 For many years, the mouse has been a workhorse of biomedical and genetic 
research. Although this organism has provided invaluable information about diseases 
and development, the dog, Canis lupus familiaris, is emerging as an equally important 
and perhaps more useful model of human hereditary diseases. Throughout history, the 
dog has proven to be a dedicated companion and tireless worker. Now, it has become an 
invaluable research model. It is, in fact, the unique relationship we have with our dogs 
that allows us to utilize them in this way. 
 Recent work indicates that that dogs were first domesticated from grey wolves 
(Vila et al., 1997; Savolainen et al., 2002) in East Asia. However, archeological and 
mitochondrial data disagree on the dates of this occurrance. Studies using mitochondrial 
DNA suggest that domestication occurred anywhere from 40,000 to 15,000 years ago 
and archeological data suggest domestication at 14,000 to 9,000 years ago  (Leonard et 
al., 2002; Savolainen et al., 2002). Through thousands of years of controlled breeding, 
humans were able to select for the characteristics they found most valuable. Some dogs 
were chosen for their speed, others for their herding abilities and still others for their 
retention of neotenous features. These animals eventually evolved into dogs such as the 
Saluki, German Shepherd Dog and Pomeranian.  
 
___________________ 
This dissertation follows the style and format of Gene. 
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 Today, there are more than 350 different breeds of dog, with the majority having 
been created in the past 250 years (Ostrander and Giniger, 1997). The phenotypic 
diversity of these breeds is staggering; among mammals, the dog is the most 
phenotypically diverse species alive today. In order to obtain and maintain the desired 
traits, much inbreeding within breeds has occurred. This has fixed desired behavioral 
and physical traits in a breed, but also resulted in selection of undesirable genetic defects 
and diseases. There are more than 450 known hereditary diseases of the dog, over half of 
which are also found in the human (Ostrander and Giniger, 1997). These diseases often 
have similar, if not identical, clinical presentations in both the human and dog, and many 
are caused by mutations in the same genes (Ostrander and Giniger, 1997).  
 The fact that canine hereditary diseases occur naturally, unlike those in the 
majority of murine models, makes the dog an extraordinary model of human diseases. In 
addition, the dog is more closely related to the human than is the mouse in both size and 
genetic make-up (Kirkness et al., 2003). The reduced heterogeneity, short generation 
times, large litters, and extensive pedigree data are also of benefit to researchers. 
Because dogs share our homes, exercise habits and food (sometimes), the contribution 
these factors play in the development and outcome of diseases can be more accurately 
studied. In addition, in the United States, dogs are provided with a level of health care 
second only to the human (Ostrander et al., 2000). Therefore, extensive medical records 
that describe symptoms, pathology and treatment of both infectious and hereditary 
diseases are available. 
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The canine genome 
 Highlighting its utility as a model organism, the dog was selecetd to have its 
genome sequence. It was the fourth mammalian genome to be sequenced. The first 
sequence of the canine was completed in 2002 genome, by Celera Genomics. Celera. 
reported a 1.5X sequence of a male standard poodle and this sequence provided 77% 
coverage and was done using a shotgun approach (Kirkness et al., 2003). Unfortunately, 
this sequence was not made publicly available. Therefore, the National Human Genome 
Research Institute (NHGRI) produced a 7.8X sequence in 2004 (Lindblad-Toh et al., 
2005). Sequencing was performed using DNA from a female boxer due to her high 
degree of genetic homogeneity with dogs representing many breeds. This sequence 
provides >95% coverage and is available for public use at 
www.ncbi.nih.gov/genome/guide/dog (Lindblad-Toh et al., 2005). The availability of 
these sequences has greatly advanced the field of canine genetics, helping researchers to 
utilize the dog to its fullest extent as a model organism.  
    
Biology of the glomerular basement membrane 
The main functional unit of the kidney is the nephron in which urine is formed. 
Each nephron consists of two main components, the glomerulus and the tubules. 
Respectively, these compartments serve to filter the blood plasma and to produce and 
refine the urine. To make the filtrate that will subsequently be processed by the tubules, 
the plasma is filtered by a selective barrier in the glomerulus consisting of 1) the 
fenestrated endothelium, 2) the glomerular basement membrane (GBM) and 3) the 
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epithelial cells (podocytes). For the purposes of this dissertation, only the GBM will be 
discussed in further detail. 
The GBM functions as a filtration barrier and, like other basement membranes, 
as a site for cell adhesion and migration. Both the endothelial cells and podocytes 
contribute to the formation of the GBM (Abrahamson, 1987). The GBM is 300-350nm 
thick and composed of three distinct layers: 1) the lamina rare interna, 2) the lamina 
densa and 3) the lamina rara externa (McCarthy, 1997). This specialized basement 
membrane is comprised of type IV collagen, laminin, fibronectin, entactin/nidogen, 
heparan sulfate proteoglycans and, in lesser amounts, types III and V collagen (Miner, 
1998). This complex protein network allows the passage of small molecules, but restricts 
the passage of molecules larger than albumin. The negatively charged proteoglycans are 
thought to contribute to filtration by blocking the passage of negatively charged plasma 
proteins (Miner, 1998).  
 
Type IV collagens 
 The type IV collagens are important components of the GBM. The network of 
type IV collagens provides the framework onto which the other GBM components are 
attached. There are six type IV collagen alpha chains: α1(IV)-α6(IV), all of which have a 
similar genomic arrangement and protein structure.  
The genes encoding the type IV collagens (COL4A1-COL4A6) are arranged in 
pairs, in a head-to-head fashion. COL4A1 and COL4A2 are found on Homo sapien 
chromosome 13 (HSA13) and Canis familiaris chromosome 22 (CFA22), COL4A3 and 
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COL4A4 are found on HSA02 and CFA25 and, finally, COL4A5 and COL4A6 are found 
on the X-chromosome in both the dog and human (Griffin et al., 1987; Boyd et al., 1988; 
Hostikka et al., 1990; Mariyama et al., 1992; Sugimoto et al., 1994; Momota et al., 1998; 
Lowe et al., 2003; Wiersma et al., 2005). COL4A1 and COL4A2 are co-expressed and 
their protein products co-localize and the same is true for the COL4A3/COL4A4 gene 
pair (Poschl et al., 1988; Timpl, 1989). Transcription of the COL4A5/COL4A6 gene pair 
is not well understood, and unlike the other type IV collagens, these genes are not 
always co-expressed (Ninomiya et al., 1995). That is, COL4A5 may be expressed in the 
absence of COL4A6.   
The type IV collagens are approximately 1700 amino acids in length and each is 
divided into three segments: 1) the N-terminal 7S domain, 2) the collagenous domain 
and 3) the C-terminal non-collagenous, or NC1, domain. The collagenous domain has a 
repetitive Gly-X-Y sequence of approximately 1400 amino acids; X and Y are most 
commonly proline or hydroxyproline. Interruptions exist in this repetitive sequence, and 
allow the molecule flexibility.   
To form a functional collagen molecule, three type IV collagen monomers will 
assemble to form a heterotrimer. The three NC1 domains will assemble, and the 
collagenous domains will form a right-handed triple helix from the carboxy to the 
animo-terminus (Boutaud et al., 2000). The proper formation of the heterotrimer is 
essential to basement membrane function. When properly formed, these heterotrimers 
will assemble to form a network by bringing two NC1 trimers together to form a dimer, 
and bringing four 7S domains together to form a tetramer (Hudson et al., 1993).  
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Although many combinations could theoretically be made, the six type IV 
collagen monomers will trimerize to form only three heterotrimers: α1.α1.α2(IV), 
α3.α4.α5(IV) and α5.α5.α6(IV) (Timpl, 1989; Gunwar et al., 1998; Sado et al., 1998). 
The α1.α1.α2(IV) heterotrimer is found ubiquitously in basement membranes (Timpl, 
1989). The α3.α4.α5(IV) heterotrimer is found in the GBM of the adult kidney, lung, 
testis, cochlea and eye (Butkowski et al., 1989; Kleppel et al., 1989; Sanes et al., 1990; 
Miner and Sanes, 1994). Finally, the α5.α5.α6(IV) heterotrimer is found in skin, smooth 
muscle, esophagus and Bowman’s capsule (Peissel et al., 1995; Borza et al., 2001). The 
disruption or absence of the α3.α4.α5(IV) heterotrimer causes  Alport syndrome and 
hereditary nephropathy. 
 
Alport syndrome and hereditary nephropathy 
Clinical aspects 
Alport syndrome (AS) and hereditary nephropathy (HN) refer to any of the 
inherited glomerular nephropathies caused by mutations in the three members of the type 
IV collagen gene family that are required for normal structure and function of the GBM. 
These diseases occur in the human (AS) and naturally in various breeds of the domestic 
dog (HN). Although this disease is not highly prevalent in the human population 
(1/50000 births), it is the second most common genetic cause of renal failure (2006).  
Both AS and HN are progressive diseases and patients inevitably progress to end-stage 
renal disease (ESRD) and the only treatment options currently available for the human 
are dialysis and renal transplantation. 
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Although the genetic causes of AS and HN are diverse, the primary structural 
abnormalities common to all forms of the disease are defects in the GBM. Secondary 
organ systems such as the cochlea and eye may also be affected to differing degrees 
(Kashtan, 1998). The kidney, however, is the primary affected organ.  
The abnormalities in the AS and HN affected kidney include a distinctive 
multilaminar splitting of the GBM, which contributes to the development of hematuria, 
proteinuria and progressive renal injury. Due to the lack of a functional α3.α4.α5(IV) 
heterotrimer in the GBM, plasma cannot be properly filtered. Damage to the glomerulus 
increases as proteins traverse the GBM and enter the Bowman’s capsule. These proteins 
are eventually excreted in the urine. Proteinuria begins as microalbuminuira and 
increases in severity because more damage to the GBM allows both larger volumes of 
protein and proteins of larger molecular weight to filter through the GBM, which the 
proximal tubules are unable to reabsorb properly. The presence of these proteins in the 
tubules can induce an inflammatory response that may lead to the infiltration of both 
lymphocytic and histiocytic cells and cause patchy fibrosis. This insult increases the 
damage to the entire nephron and eventually renders it nonfunctional. As more nephrons 
are lost, the survivors are forced to increase their workloads in order to maintain 
extracellular fluid homeostasis. The glomeruli in these nephrons, however, also have an 
abnormal GBM and due to the increased workload, damage to both the glomerulus and 
tubules progresses at an increased rate. Once the surviving nephrons are too few in 
number, the patient suffers renal failure. Therefore, it is the accumulation of structural 
and functional damage to the entire kidney that leads to ESRD.   
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Genetics  
 Both AS and HN are caused by mutations in the type IV collagen genes, 
specifically COL4A3, COL4A4 and COL4A5. As previously written, the protein products 
of these three genes form the α3.α4.α5(IV) heterotrimer that localizes to the GBM. AS 
and HN can be transmitted in autosomal recessive, autosomal dominant and X-linked 
fashions.  
 The majority of AS and HN cases (>85%) are transmitted in an X-linked fashion 
(Kashtan, 1998). These cases are due to mutations occurring in the COL4A5 gene, which 
is located on both the human and canine X-chromosomes (Hostikka et al., 1990; 
Sugimoto et al., 1994). Males affected with this disease will develop proteinuria early in 
life, progressing to ESRD early in the second decade of life. Females will be 
heterozygous for the causative mutation and will progress at various rates, possibly due 
(in part) to different patterns of X-chromosome inactivation (Vetrie et al., 1992). The 
remaining ~15% of cases are autosomal recessive and occur due to mutations in either 
the COL4A3 or COL4A4 genes, located on HSA02 and CFA25 (Lowe et al., 2003; 
Wiersma et al., 2005). There have been few documented cases of autosomal dominant 
AS and HN, also due to mutations in COL4A3 or COL4A4 (Pescucci et al., 2004). 
 
Animal models  
 Currently, there exist three animal models of X-linked AS and HN, two of which 
are naturally occurring canine models and one of which is a “knock-in” murine model. 
The first canine model discovered was the Samoyed model in 1977 (Bernards and Valli, 
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1977). These dogs transmit HN in an X-linked fashion (XLHN) with pathology similar 
to that seen in human XLAS. These dogs exhibit increasing proteinuria and enter ESRD 
at an average of eight to ten months of age (Jansen et al., 1987). Staining for the α3(IV), 
α4(IV) and α5(IV) proteins in the GBM revealed a complete absence of this heterotrimer 
(Thorner et al., 1989). Unlike many human cases of XLAS, however, these dogs do not 
exhibit any of the extra-renal manifestations such as ocular abnormalities or 
sensorineural deafness (Thorner et al., 1988). Therefore, the most accurate term for this 
disease is HN. Further work revealed that HN in this Samoyed model is due to a 
nonsense mutation in exon 35 of COL4A5 (Zheng et al., 1994).  
 The second canine model was documented in 1993 by Dr. George E. Lees of 
Texas A&M University (Lees et al., 1999). These dogs were brought to the Small 
Animal Clinic at Texas A&M when some of the males in a family developed adolescent 
renal failure. The clinical, pathological and immunohistochemical findings were 
consistent with human XLAS (Lees et al., 1999). As in human XLAS and the XLHN 
Samoyed model, there was a lack of staining for α3(IV), α4(IV) and α5(IV) proteins in 
the GBM of affected individuals (Lees et al., 1999). Also like the Samoyed model, these 
dogs lack any auditory or ocular abnormalities. In 1998 Dr. Lees established a colony of 
dogs that present with XLHN using semen from two of the originally affected males. 
This colony was used to further characterize this disease. The colony contains normal 
dogs of both genders, XLHN-affected males and XLHN-carrier females. Sequencing of 
the coding region of COL4A5 revealed a ten base pair deletion in exon nine and this 
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causes a frameshift leading to a premature stop codon in exon ten (Cox et al., 2003). 
These dogs are termed NAV dogs, due to their city of origin, Navasota, Texas. 
 The affected males in this colony initially show proteinuria at three to four 
months of age and reach ESRD between ten and fifteen months of age (Lees et al., 
1999). Female carriers have a much longer life-span compared to the affected male NAV 
dogs. The carriers become proteinuric at approximately four months of age; this 
proteinuria will increase until about 12 months of age. At this point, the proteinuria is 
stable and the dogs may live a long life with acceptable renal function, a phenomenon 
that is not well understood.  
In 2004 the third model of XLAS, a murine model, was described by Rheault et 
al. (Rheault et al., 2004). This model was produced by the introduction of a nonsense 
mutation into the first exon of COL4A5 (Rheault et al., 2004). Affected males show an 
absence of α5(IV) staining in the GBM and die between six and 34 weeks of age. 
Female carriers show a mosaic pattern of staining for α5(IV) and die at eight to 45 weeks 
of age. These animals show a pattern of disease progression similar to that seen in 
humans and are, therefore, an animal model of this disease.  
 In addition to the canine models of XLHN, there also exists a naturally occurring 
canine model of autosomal recessive HN (ARHN). This disease was first documented 
approximately 50 years ago by Dr. Krook at the Royal Veterinary College in Stockholm 
Sweden (Krook, 1957). He described Cocker Spaniels presenting with renal cortical 
hypoplasia. This term was later refined to familiar nephropathy and later again to 
hereditary nephropathy. In 1992 when an English Cocker Spaniel (ECS) presented with 
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distinctive GBM ultrastructural changes at Texas A&M University, a systematic study of 
this disease was undertaken by Dr. Lees (Lees et al., 1997). Because this disease was 
clearly inherited in an autosomal recessive fashion, COL4A3 and COL4A4 were the two 
candidate genes. A nonsense mutation was found in exon three of COL4A4 is causative 
for the disease (Davidson et al., 2007).  
 Three murine models of autosomal recessive AS (ARAS) have also been 
produced. Two of these have knockouts in COL4A3, and the third has knockouts in 
COL4A3 and COL4A4 (Cosgrove et al., 1996; Miner and Sanes, 1996; Lu et al., 1999). 
All three models have clinical phenotypes similar to that of humans with ARAS and all 
homozygous mutants lack the α3.α4.α5(IV) heterotrimer in the GBM. 
 
Specific objectives 
 The first objective of this work was to develop a genomic based test to accurately 
determine the genotype of mixed breed dogs in a colony that has members with XLHN. 
This test was developed using the publicly available canine genome sequence and the 
implementation of this test will allows for planning of ongoing studies. The second 
objective was to design a canine COL4A5 cDNA to be used for a gene transfer treatment 
of XLHN. The coding sequence of this gene was modified to suit our requirements and 
synthesized by a private company. The third objective of this work was to examine X-
chromosome inactivation patterns in female carriers of XLHN. A methylation sensitive 
PCR assay was used to determine patterns of X-chromosome inactivation and the results 
were compared to normal females dogs of the same colony. The fourth objective was to 
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examine type IV collagen gene expression changes in dogs affected with XLHN and 
ARHN. In doing so, this allowed for the completion of the final objective, the 
identification of the mutation causative for ARHN in the ECS.   
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CHAPTER II 
DEVELOPMENT OF A GENOMIC TEST FOR X-LINKED HEREDITARY 
NEPHROPATHY IN A MIXED BREED DOG 
Overview 
A colony of mixed breed of dogs, termed Navasota or NAV dogs, which has 
XLHN, was established at Texas A&M University. This colony is an ideal model for the 
study of human XLAS. When this colony was first established, genotypes were 
determined by skin immunohistochemistry. After the discovery of the causative mutation 
in COL4A5, RNA was used as the template for the detection of the deletion. However, 
these tests were not as easily performed, or as accurate as was desired. Therefore, a test 
based on the genomic DNA sequence of COL4A5 was developed. The sequence of the 
amplicon was verified and dogs of known clinical status were genotyped. All resulting 
genotypes were consistent with clinical status. This test allows the genotype of the NAV 
dogs to be determined at an early age. The test is 100% accurate and more than 200 dogs 
have been genotyped.   
 
Introduction 
 In 1998 Dr. George Lees established a colony of mixed-breed dogs, termed NAV 
dogs, which present with XLHN (Lees et al., 1999). These dogs proved to be an 
excellent model for the study of human XLAS because the cause of disease and 
progression of disease are similar. Both XLHN and XLAS are caused by mutations in 
the COL4A5 gene which is located on the human and canine X-chromosomes (Hostikka 
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et al., 1990; Sugimoto et al., 1994). In the NAV dogs, this disease is caused specifically 
by a ten base pair deletion in exon nine of COL4A5 (Cox et al., 2003).  
 This colony of dogs provides researchers with the ability to study not only 
XLHN but also to investigate various aspects of canine chronic renal failure and its 
management. In order to properly plan experiments and for the disease progression to be 
properly monitored, it is essential to know the genotypes of all dogs at an early age. 
 Before the causative mutation was identified, the preferred method of diagnosis 
was immunohistochemistry of skin. This method detected the α5(IV) protein in the 
epidermal basement membrane (EBM). This required skin biopsies to be taken, which is 
an invasive procedure for a young dog to endure. In addition, this method of diagnosis 
had a history of false results, especially for the carrier females.  
 After the identification of the causative mutation, genetic status was determined 
by detection of the ten base pair deletion using RNA as the template. RNA was used 
because, at that time, only the coding sequence of the gene was known. This method was 
also problematic because RNA had to be isolated from either skin biopsies (again, an 
invasive procedure) or blood, which is an unreliable source. In addition, work using 
RNA is, at times, difficult. 
 With the publication of the canine genome sequence by the NHGRI in 2004 
(Lindblad-Toh et al., 2005), the entire sequence of the COL4A5 gene was made available 
and a genomic test could be developed that is both accurate and noninvasive. Genomic 
DNA is more easily obtained than either skin biopsies or RNA and can be easily isolated 
from blood or buccal swabs. The collection of buccal swabs is ideal because it is 
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noninvasive and can be performed when the dogs are only a few days old. The use of 
this test has proven to be fast, economical and 100% accurate.    
 
Materials and methods 
 DNA was isolated from blood or buccal swabs using the Puregene DNA 
Purification kit according to the manufacturer’s instructions (Gentra Systems, Inc., 
Minneapolis, MN). DNA was isolated from tissue using the Qiagen DNeasy kit (Qiagen 
Inc., Valencia, CA). Quantity and quality of DNA were determined by 
spectrophotometry using a NanoDrop 1000 (NanoDrop Tech., Wilmington, DE). 
Primers in the intronic regions flanking exon nine of COL4A5 were designed 
based on the published canine genome sequence. These primers were designed to 
amplify 202 base pairs of sequence including exon nine of COL4A5: Forward 5′-
CGCTTGACTATTTTGTGTGTCATAA-3′, Reverse 5′-
AAGGTGATGCTGTGATCTGATTTA-3′.   Amplification by PCR was carried out with 
each 10µl reaction containing 50ng of DNA, 3.0mM of MgCl, 0.5mM of each dNTP, 
1.0µM of each primer (forward and reverse), 1X MasterAmp (Epicentre 
Biotechnologies, Madison, WI, USA), 1X Taq DNA Polymerase Buffer B (Fisher 
Scientific, Pittsburgh, PA, USA) and 0.04 U/µl of Taq DNA Polymerase (Fisher 
Scientific). Cycling conditions were as follows: 95°C for two minutes, followed by five 
cycles of 95°C for 30 seconds, 58°C for 15 seconds and 72°C for ten seconds, followed 
by an additional 30 cycles of 95°C for 20 seconds, 56°C for 15 seconds, 72°C for ten 
seconds and then a single cycle at 72°C for five minutes.  
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The product sequence was initially verified by purifying seven µl of the PCR 
product using 10U of Exonuclease I (Epicentre) and 1U of Shrimp Alkaline Phosphatase 
(Roche, Indianapolis, IN, USA) incubated at 37°C for 30 minutes, followed by a 15 
minute incubation at 80°C. The Big Dye Terminator v 1.1 Cycle Sequencing Kit 
(Applied Biosystems, Foster City, CA) was used, following the manufacturer protocol, 
for nucleotide sequencing. Sequences were resolved on an ABI3130 (Applied 
Biosystems). All subsequent genotypes were resolved on an ABI3130 and analyzed 
using Genotyper or Genemapper software (Applied Biosystems).  
 
Results and discussion 
 The sequencing results confirmed that the primers amplified exon nine of 
COL4A5 and the 59 base pairs and 60 base pairs in introns eight and nine, respectively. 
The sequence of exon nine of COL4A5 of normal dogs shows no point mutations, 
insertion or deletions but affected dogs have the ten base pair deletion in this gene.  
   To assure that the test was indeed accurate, genotypes from known normal dogs 
of both genders, XLHN-affected males and XLHN-carrier females were determined in a 
blind test. XLHN-affected males had a single product at 192 base pairs, normal dogs of 
both genders had a single product at 202 base pairs and XLHN-carrier females had two 
products; one at 192 and the other at 202 base pairs. Examples of results are in Figure 
2.1. All genotypes were consistent with the known clinical status of the dogs. 
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Fig. 2.1. Example of a mutation based test for X-linked hereditary nephropathy in the 
Navasota dog. Shown are Dog 1 (affected male), Dog 2 (normal male) and Dog 3 
(carrier female). 
 
 
 
  To date over 200 NAV dogs have been genotyped and the accuracy of this test is 
100%. Buccal swabs can be collected when dogs are only a few days old and results are 
available within two weeks of birth. This method allows for better planning for future 
procedures involving these dogs.  
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CHAPTER III 
 
X-CHROMOSOME INACTIVATION PATTERNS IN NORMAL AND X-
LINKED HEREDITARY NEPHROPATHY CARRIER DOGS 
Overview 
AS and HN are glomerular nephropathies caused by mutations in the genes 
encoding the type IV collagens. In a mixed breed of dog, NAV dogs, XLHN is caused 
by a ten base pair deletion in exon nine of COL4A5. Males harboring this mutation 
succumb to end-stage renal disease before 18 months of age. In contrast, female carriers 
of this disease survive much longer, most have a normal life-span, and vary in disease 
progression as compared with XLHN-affected males. X-chromosome inactivation (XCI) 
patterns have been studied in human X-linked AS carriers and some have been shown to 
have a high degree of skewed XCI. However, similar studies have never been reported in 
an animal model of this disease. Therefore, patterns of XCI were examined in XLHN-
carrier NAV dogs. The variation in XCI among the 26 XLHN-carrier and seven normal 
female NAV dogs studied was low and only three were found to be highly skewed 
(>80%). The average skewedness among all dogs was 59%. Of these 33 dogs, the 26 
XLHN-carriers showed an average skewedness of 57%, and all three of the highly 
skewed dogs were carriers. When the two groups were compared using Fisher’s exact 
test, no significant difference was found (P=0.477). Given the low variance among the 
dogs studied and the mean skewedness of 59%, it is clear that the majority of these dogs 
have random X-chromosome inactivation. In this population, genotype does not seem to 
have an effect on X-chromosome inactivation. Highly skewed X-chromosome 
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inactivation also appears to be random, given that no difference was observed between 
the XLHN-carriers and normal females. Because of the low amount of skewedness seen, 
these dogs may not be a suitable model in which to study a potential correlation between 
X-chromosome inactivation and disease progression.  
     
Introduction 
 AS and HN refer to any of the inherited glomerular nephropathies caused by 
mutations in any of the three members of the type IV collagen gene family that are 
required for normal glomerular basement membrane (GBM) structure and function. 
These conditions occur in both the human (AS) and the domestic dog (HN). Both AS 
and HN can be inherited in three fashions: X-linked, autosomal recessive and autosomal 
dominant.  
The COL4A5 gene is located on the X-chromosome in both the human and the 
dog and mutations in this gene are responsible for the X-linked forms of AS and HN. 
Unlike the autosomal forms of AS and HN, males and females harboring a COL4A5 
mutation exhibit drastically different phenotypes (Jansen et al., 1987; Hostikka et al., 
1990; Lees et al., 1999; Jais et al., 2000; Jais et al., 2003; Lowe et al., 2003). Because 
they are hemizygous, affected male humans and dogs will have only a mutated copy of 
the COL4A5 gene and will, on average, progress quickly to ESRD. Alternatively, female 
carriers of both species are heterozygous (having both a wild type and mutated copy of 
the gene) and human female carriers exhibit highly variable phenotypes, ranging from 
mild hematuria to ESRD (Jais et al., 2003).   
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 Currently, there exist two spontaneously occurring canine models of XLHN: 1) a 
Samoyed kindred and 2) a kindred of a mixed breed dog, termed NAV dogs (Bernards 
and Valli., 1977; Lees et al., 1999). The Samoyed kindred harbors a nonsense mutation 
in exon 35 of COL4A5 and the NAV kindred harbors a ten base pair deletion in exon 
nine of COL4A5, leading to a premature stop codon in exon ten (Zheng et al., 1994; Cox 
et al., 2003). In addition, an X-linked AS (XLAS) murine model has been engineered to 
have a nonsense mutation in exon one of COL4A5 (Rheault et al., 2004). 
 XLHN-affected males in the NAV kindred tend to progress at similar rates, with 
the onset of proteinuria at three to four months, and ESRD by six to15 months of age 
(Lees et al., 1999). XLHN-carrier NAV females exhibit clinical manifestations similar to 
the XLHN-affected males in that all will develop proteinuria, but the magnitude of 
proteinuria varies and the rate of disease progression is slower (Lees et al., 1999). 
Proteinuria is first detected in carriers at an average of four months of age and will 
increase until approximately 12 months of age, at which point it will remain stable for 
many years. Most XLHN-carrier NAV dogs have a normal life span, which is 
substantially longer than their affected male counterparts. This ability to retain stable 
renal function for many years is a phenomenon that is not well understood.  
 It has been proposed that the high degree of variation in human female XLAS 
carriers may be due, in part, to non-random (skewed) X-chromosome inactivation (XCI) 
patterns, and multiple studies have investigated this phenomenon (Vetrie et al., 1992; 
Guo et al., 1995; Nakanishi et al., 1998; Shimizu et al., 2006; Kashtan, 2007). Despite 
their availability, to date, no studies have reported XCI patterns in any of the existing 
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animal models of X-linked AS and HN. Therefore, this investigation was carried out in 
order to determine the XCI patterns in normal and XLHN-carrier NAV dogs.  
The XCI patterns in seven normal and 26 XLHN-carrier female NAV dogs were 
studied using an assay similar to that used in human studies. Two variable length CAG 
repeats found in the first exon of the androgen receptor (AR) gene can be used to 
distinguish the paternal and maternal X-chromosomes (Shibuya et al., 1993; Lu et al., 
2001). XCI patterns in the 33 female NAV dogs were determined using a methylation-
sensitive PCR assay that analyzes one of these CAG repeats (Allen et al., 1992). In order 
to decrease the need for tissue samples, an initial study was performed to test the 
correlation of XCI patterns found in peripheral blood and renal tissue. There was a high 
degree of correlation between the two sample types and this allowed additional dogs to 
be profiled using only peripheral blood. Few XLHN-carriers NAV dogs were found to 
be highly skewed and variation within the population was very low. These findings 
demonstrate that, in this population, the genotype of females does not seem to influence 
XCI. The apparent rarity of skewed XCI in this population complicates any future 
studies to correlate XCI patterns and disease progression. Any phenotypic variation seen 
in this population is likely due to other contributing genetic factors.  
 
Materials and methods 
Genotype determination and sample collection 
Buccal swabs collected at birth were used to determine genotype of the NAV 
dogs by PCR amplification of exon nine of COL4A5 using the following intronic 
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primers: Forward 5′-CGCTTGACTATTTTGTGTGTCATAA-3′, Reverse 5′-
AAGGTGATGCTGTGATCTGATTTA-3′. Amplification by PCR was carried out with 
each 10µl reaction containing 50ng of DNA, 3.0mM of MgCl, 0.5mM of each dNTP, 
1.0µM of each primer (forward and reverse), 1X MasterAmp (Epicentre 
Biotechnologies, Madison, WI), 1X Taq DNA Polymerase Buffer B (Fisher Scientific, 
Pittsburgh, PA) and 0.04 U/µl of Taq DNA Polymerase (Fisher Scientific). Cycling 
conditions were as follows: 95°C for two minutes, followed by five cycles of 95°C for 
30 seconds, 58°C for 15 seconds and 72°C for ten seconds, followed by an additional 30 
cycles of 95°C for 20 seconds, 56°C for 15 seconds, 72°C for ten seconds and then a 
single cycle at 72°C for five minutes. Genotypes were resolved on an ABI 3130 and 
analyzed using Genemapper software (Applied Biosystems, Foster City, CA).  
For the reported study, peripheral blood was collected from 25 XLHN carrier, 
seven normal female NAV dogs and one normal male control (as a digestion control) 
and stored in EDTA tubes. Renal tissue from ten dogs was collected by biopsy or at the 
time of necropsy. Tissue was either frozen in liquid nitrogen or stored in RNAlater 
(Ambion Inc., Austin, TX).  
 
DNA isolation 
 DNA was isolated from blood and buccal swabs using the Puregene DNA 
Purification kit, and the manufacturers instructions were followed (Gentra Systems, Inc., 
Minneapolis, MN). DNA was isolated from tissue using the Qiagen DNeasy kit (Qiagen 
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Inc., Valencia, CA). Quantity and quality of DNA were determined by specrophotometry 
using a NanoDrop 1000 (NanoDrop Tech., Wilmington, DE).  
 
Sequencing of a portion of the canine androgen receptor gene 
 Primers used to amplify the first and second CAG repeats in the canine AR 
gene are as follows: Forward 5′- CGAAGTGATCCAGAACCCGG-3′, Reverse 5′-
GCTACCTGGCTCTGGATGAGGAA-3′ and Forward 5′- 
CCCATCCACATTGTCACTGCTG-3′, Reverse 5’- 
CATGGACACCGACACTGCCTT-3′, respectively. Each reaction contained 50ng of 
DNA, 3.0mM of MgCl, 0.5mM of each dNTP, 1.0µM of each primer (forward and 
reverse), 1X MasterAmp (Epicentre Biotechnologies), 1X Taq DNA Polymerase Buffer 
B (Fisher Scientific) and 0.04 U/µl of Taq DNA Polymerase (Fisher Scientific). Reaction 
conditions were as follows: 95°C for five minutes, followed by 33 cycles of 95°C for 30 
seconds, 60°C for 15 seconds and 72°C for ten seconds and a single cycle at 72°C for 
five minutes. Seven µl of the PCR product was purified using 10U of Exonuclease I 
(Epicentre) and 1U of Shrimp Alkaline Phosphatase (Roche, Indianapolis, IN) and 
incubated at 37°C for 30 minutes, followed by a 15 minute incubation at 80°C. The Big 
Dye Terminator v 1.1 Cycle Sequencing Kit (Applied Biosystems) was used, following 
the manufacturer protocol, for nucleotide sequencing, sequences were resolved on an 
ABI3130 (Applied Biosystems).  
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X-chromosome inactivation analysis 
 Two hundred ng of DNA was combined with 1U each of the methylation- 
sensitive restriction enzymes HpaII and HhaI in a 50µl reaction with 1X Buffer 4 and 
100 µg/ml Bovine Serum Albumin (New England Biolabs, Inc., Ipswich, MA). In 
addition, undigested controls of each sample were incubated in 50µl reactions without 
the restriction enzymes. This served as a control for any effects the restriction enzyme 
buffers may have had on subsequent PCRs. All reactions (digested and undigested) were 
incubated for 16 hours at 37°C followed by inactivation for 20 min at 65°C.  
 From each of the digested and undigested DNA samples 25ng was used for the 
subsequent PCR. All dogs were analyzed for either the first or second CAG repeat in the 
AR gene using the primers and conditions described in the previous section. All reactions 
were run in triplicate to ensure reproducible and accurate results. 
 Genotypes were resolved on an ABI 3130 and analyzed using Genemapper 
software (Applied Biosystems). Degree of skewedness was determined by comparing the 
peak areas of the digested and undigested samples. The following calculation was used: 
skewing= (Bd1/Bu1)/[(Bd1/Bu1)+(Bd2/Bu2)] where B1 and B2 represent the first and 
second alleles, respectively, and Bd and Bu represent the digested and undigested 
samples, respectively (Lau et al., 1997). 
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Statistical analysis  
 A paired Student’s t-test was used to compare the inactivation patterns seen in 
blood and tissue (α=0.01). Fisher’s exact test was used to compare the occurrence of 
highly skewed individuals in the XLHN-carriers and normal females. 
 
Results and discussion 
X-chromosome inactivation 
 The fact that females have two X-chromosomes gives them an obvious advantage 
in X-linked diseases. Unlike males, who have only one X-chromosome, a female must 
carry a mutation on both X-chromosomes to be fully affected by an X-linked disease, 
and this is a rare occurrence. Typically, males will be fully affected and carrier females 
will show a range of symptoms between normal and affected. 
 It has been hypothesized that this range of symptoms may be due to unequal, or 
skewed, XCI (Vetrie et al., 1992). In a female, each cell must inactivate one X-
chromosome as a mechanism of dosage compensation (Lyon, 1961). As this is thought 
to be a random process, most females will have a 50:50 ratio of maternal to paternal 
XCI. However, there are documented cases of unequal, or skewed, XCI (Guo et al., 
1995; Lau et al., 1997; Uz et al., 2007). Skewing favors the inactivation of one X-
chromosome over the other, and when this occurs in carriers of an X-linked disease it 
can have an effect on the clinical presentation. If the X-chromosome harboring a 
mutation is more often active, the phenotype may be more severe because less of the 
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normal protein is produced. In contrast, if it is the wild-type X-chromosome that is more 
often active, the phenotype may be more like that of a normal female.  
 Reports of human carriers of XLAS have shown that a wide range of phenotypes 
exist. An extensive study by Jais et al. found carriers developing ESRD as early as age 
19, while some retained adequate renal function into and beyond the sixth decade of life 
(Jais et al., 2003). Some human XLAS-carriers with early ESRD have been shown to 
have skewed XCI and it has been proposed that differences in XCI may account for 
some differences in phenotype (Vetrie et al., 1992; Guo et al., 1995). Similar studies 
involving any of the previously described animal models of AS or HN have not been 
reported. Thus, this study was done to investigate the patterns of XCI in XLHN-carrier 
and normal female NAV dogs. 
 
Analysis of X-chromosome inactivation 
 To estimate XCI patterns, a methylation sensitive PCR that amplifies one of the 
CAG repeats in the first exon of the AR gene was used. This assay has been successfully 
used for studies of human diseases since 1992 (Allen et al., 1992). Differences in the 
lengths of the two repeats in the first exon of the canine AR gene, and the one found in 
the human, can be used to distinguish the paternal and maternal X-chromosomes 
(Shibuya et al., 1993; Lu et al., 2001). The DNA analyzed using this method of analysis 
was first digested by two methylation-sensitive restriction enzymes: HpaII and HhaI. 
Due to the mechanism of XCI, the inactive X-chromosome and the AR gene located on it 
will be methylated, preventing digestion by HpaII and HhaI. In contrast, the DNA on the 
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active X-chromosome is unmethylated and is easily digested. The DNA from the initial 
digest was then used in a PCR that amplifies the aforementioned CAG repeat. Because it 
was protected from digestion, only the DNA located on the inactive X-chromosome will 
be amplified. The degree of skewedness is expressed as a ratio of the products amplified 
from the two alleles. An example of highly skewed and unskewed individuals can be 
seen in figure 3.1.  
 DNA from a male was used as a standard control for this assay because the single 
X-chromosome will be active and unmethylated. That is, when the digestions work 
properly, there cannot be any amplification because the DNA encoding the AR gene has 
been completely digested. This was found to be the case in our control (Fig. 3.1). 
 Prior to their inclusion in the study, over 50 dogs were genotyped for the CAG 
repeats because only those that were heterozygous for at least one of these alleles would 
be informative. Due to the breeding structure of this colony a majority of dogs were 
homozygous and therefore excluded, reducing the sample size. In addition, the second 
repeat was found to be less informative than the first, so the majority of dogs were 
assayed using the first CAG repeat. The recent introduction of a new sire increased the 
heterogeneity of this population, and the majority of dogs used in this study were his 
offspring. 
 
Comparison of blood and tissue samples 
 Because HN is a renal disease, any XCI patterns studied should ideally be 
performed using renal tissue. However, most studies have used peripheral blood, 
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although some have used skin biopsies (Vetrie et al., 1992; Guo et al., 1995; Nakanishi 
et al., 1998; Shimizu et al., 2006; Wang et al., 2007). One study provided evidence that 
 
 
 
 
 
 
 
Fig. 3.1. Genotypes from a normal male control, and skewed and unskewed XLHN-
carrier NAV dogs.Genotypes from digested and undigested DNA samples are shown. No 
product is seen for the digested male control because HpaII and HhaI digestion of the X-
chromosome was complete. The genotypes from the two undigested XLHN-carrier 
female DNA samples show two alleles (198 and 201). The genotypes from the two 
digested XLHN-carrier female DNA samples differ because of different patterns of XCI. 
XLHN-carrier #1 has highly skewed XCI, and therefore the peak heights of the two 
alleles are strikingly different. XLHN-carrier #2 has equal XCI, both alleles amplify 
equally well after digestion. 
 
 
 
XCI patterns in blood accurately estimate XCI patterns in renal tissue, but this was 
performed with only one sample and therefore needs further verification (Guo et al., 
1995). Sharp et al. conducted an extensive study in normal women, which showed that, 
in spite of a few outliers, there was an overall significant correlation between blood, 
U
nd
ig
es
te
d 
D
N
A
 
D
ig
es
te
d 
D
N
A
 
Male Control XLHN-Carrier 1 XLHN-Carrier 2 
198 
198
 201 201 
198
198
198
201
201 
198 
94%   6% 54%   46% 
 29
buccal swab and urinary epithelial samples (Sharp et al., 2000). In a more recent study 
Uz et al. reported similar patterns of XCI in blood and buccal swab samples of seven 
patients with pre-eclampsia (Uz et al., 2007). In order to verify previous findings and 
reduce the need for renal tissue (because obtaining it is an invasive procedure), samples 
of blood and tissue from eight XLHN-carrier NAV dogs were compared.  
 XCI patterns in blood and tissue samples were compared using a Student’s t-test. 
No statistical difference was found for all but two pairs of samples (P=0.0210, 0.0320, 
0.0204, 0.3054, 0.6227, 0.6726; α=0.01). Although the P values obtained from the 
remaining pairs indicate that there is a difference between the skewedness in blood and 
tissue (P=0.0002 and P=0.0059), neither sample type showed a high degree of 
skewedness. That is, the skewedness patterns seen in the first pair (P=0.0059) were 60% 
and 51% for blood and tissue, respectively. For the second pair (P=0.0002) the 
skewedness was 44% and 65% for the blood and tissue samples, respectively. Even with 
the presence of two outliers, these data seems to support the previously reported 
correlation in XCI patterns between blood and tissue.    
 Based on these finding and those previously reported, blood from 24 additional 
female NAV dogs was used in the remainder of the study. Although renal tissue remains 
the ideal source of DNA for this type of study, these data support previous reports and 
allowed this study to use peripheral blood in place of renal tissue. 
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 X-inactivation patterns in normal and XLHN-carrier NAV dogs 
 XCI patterns were studied in a total of 33 female NAV dogs; 26 XLHN-carriers 
and seven normals. Blood was available from all but two dogs (as they were already 
deceased); however, tissues from these two dogs were available for analysis. 
Skewedness patterns ranged from 26% to 94% inactivation of the X-chromosome with 
the wild-type COL4A5 (Fig. 3.2). The average skewedness among all dogs was 59%, 
indicating random and equal XCI. The variance and standard deviation among the 33 
dogs were low, 0.026 and 0.161, respectively. The low variance and standard deviation 
demonstrate that the sample size was sufficient.  
Within the group of 26 XLHN-carriers, the variance and standard deviation were 
0.029 and 0.172, respectively. The mean skewedness was 57%, again showing that, on 
average, there was completely random and equal XCI. Among all dogs, only three were 
found to be highly skewed (>80%) and all were XLHN-carriers. These carriers were 
81%, 85% and 94% skewed towards inactivation of the X-chromosome with the wild-
type COL4A5. It is reasonable to conclude that these dogs would express significantly 
more of the mutated α5(IV) protein than the wild-type. The low number of highly 
skewed individuals (9% of the total sample population) suggests that skewed XCI is a 
rare occurrence.  
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Fig. 3.2. Number of XLHN-carrier females in groups by percent skewedness. This graph 
shows the distribution of carriers as percent skewedness increases. The majority of dogs 
are found between 40% and 70% skewedness. This graph demonstrates that most 
XLHN-carriers are not skewed; most show a random pattern of XCI.  
 
 
 The use of Fisher’s exact test to compare the XCI patterns in XLHN-carrier and 
normal dogs showed that there was no difference between the two groups (P=0.47654). 
Even when the threshold for skewed inactivation was lowered to 70%, the P value 
remained high (0.10313). It has been proposed that carriers of X-linked diseases may 
more often exhibit skewed XCI as a response to the mutation they carry on the X-
chromosome, but the majority of studies show that this is a random event (Orstavik, 
2006). These data confirm these previous findings; no correlation between clinical status 
and skewed XCI was observed in female NAV dogs.  
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X-chromosome inactivation and age 
 The correlation between age and skewed XCI has been shown to be high in some 
cases (Kristiansen et al., 2003; Hatakeyama et al., 2004) . In theory, as a woman ages, 
her degree of skewedness may become more pronounced due to selective pressures on 
certain cell populations, and higher degrees of skewed XCI have been shown in women 
of advanced age (Kristiansen et al., 2003) . However, a longitudinal study reported in 
2004 found no difference in XCI in blood samples taken 20 years apart (Sandovici et al., 
2004). For the current study, ages of the dogs at the time of sample collection ranged 
from two to 114 months of age, with an average age of 29 months. Among the three 
XLHN-carriers shown to have highly skewed XCI, one was seven month of age and two 
were 23 months of age. Therefore, in this population those dogs of older age (>60 
months) did not display a higher rate of skewed XCI (Fig. 3.3).  
 This study is the first to report the use an animal model to investigate XCI 
patterns in carriers of XLHN or XLAS. These results provide further evidence that 
peripheral blood accurately estimates the degree of skewedness found in the kidney of 
XHLN-carriers. The use of blood in future XLHN and XLAS XCI analyses will allow 
for long term studies to be conducted. In addition, the data have shown that with the 
exception of three dogs, very similar patterns of XCI exist in this sample population. 
Therefore, the presence of the COL4A5 mutation in these carriers does not seem to 
induce a skewed pattern of XCI. Although additional studies to correlate disease 
progression and XCI patterns could be performed, the apparent rarity of highly skewed 
individuals makes conducting such studies impractical. 
 33
 
 
Skewedness and Age
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0-12 13-24 37-48 73-84 85-96 109-120
Age (months)
A
ve
ra
ge
 S
ke
w
ed
ne
ss
 
Fig. 3.3. Percent skewedness based on age. Average percentage of XCI is plotted in 
relation to age. As age increases, there is not a corresponding increase in XCI. 
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CHAPTER IV 
DESIGN OF A SYNTHETIC COL4A5 GENE FOR GENE THERAPY IN X-
LINKED HEREDITARY NEPHROPATHY DOGS 
Overview 
AS and HN are hereditary glomerular nephropathies in the human and the dog, 
respectively. These diseases are caused by mutations in the type IV collagens and are 
transmitted most often in an X-linked fashion, due to mutations in the COL4A5 gene. 
Affected patients develop hematuria, proteinuria and eventually ESRD. There are no 
cures for these diseases; the only treatment options for humans are dialysis and renal 
transplantation. Gene therapy, however, has been proposed as a treatment for AS and 
HN. A colony of mixed breed dogs, NAV dogs, which present with XLHN, was 
established at Texas A&M University. This colony has the potential to be used in gene 
therapy trials for treatment of XLHN. To this end, a COL4A5 cDNA sequence was 
modified and synthesized with the goal of introducing it into the kidneys of affected 
dogs. The cDNA sequence was modified in order to facilitate its cloning into various 
vectors and also to distinguish the protein product from native α5(IV). By introducing 
this wild-type gene, it is possible that the resulting protein will be deposited into and aid 
in the repair of the GBM.  
 
Introduction 
 AS and HN are hereditary glomerular diseases that result in ESRD. Although HN 
is uncommon in the dog and AS accounts for only approximately 3% of all ESRD in 
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humans, study of the disease process offers the potential to increase our understanding of 
ESRD (Agodoa et al., 1996). The only therapies currently available for people with AS 
are dialysis and renal transplantation. However, these options are expensive, the waiting 
lists for transplants are long and many people never receive the transplant they need to 
survive. Dialysis and transplantation are currently not feasible options for dogs with HN, 
but other medical treatments to slow disease progression are similar.  
   Gene therapy has been proposed as a potential treatment for XLAS and XLHN 
because these diseases are caused by mutations in a single gene (COL4A5). Previous 
studies demonstrated that the human COL4A5 cDNA could be introduced into porcine 
kidneys by perfusion with subsequent α5(IV) deposition in the GBM (Heikkila et al., 
2001). This work provided encouraging results for future gene therapy experiments. 
However, in order to reduce the possibility of immune reactions, the coding sequence 
used should be from the same species, i.e. in a canine model, the canine COL4A5 
sequence should be used. In addition, experiments need to be performed that show that 
this form of therapy can slow disease progression. Thus, we are trying similar treatments 
in the NAV dog model of XLHN using a canine-specific cDNA. The ultimate goal is for 
the wild-type COL4A5 cDNA to be expressed, and for the encoded protein to 
subsequently be deposited into the GBM of affected dogs. To this end, we have designed 
and synthesized a COL4A5 cDNA.  
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Materials and methods 
Design and synthesis of COL4A5 cDNA 
 Modifications made to the COL4A5 cDNA sequence were as follows: 1) a FLAG 
epitope was inserted into the fifth collagenous interruption and 2) unique restriction sites 
were added to the 5′ and 3′ ends of the sequence (Fig. 4.1). The resulting sequence was 
checked using BCM Search Launcher (http://searchlauncher.bcm.tmc.edu/) to assure that 
the reading frame and amino acid sequence were maintained. Once the nucleotide 
sequence was modified, it was sent to Blue Heron Biotechnologies 
(http://www.blueheronbio.com/) (Blue Heron Biotechnologies, Bothell, WA) for 
synthesis. The cDNA was cloned into the Blue Heron Bio pUCminus vector and 
sequenced verified by Blue Heron Biotechnologies. 
 
Transfer of COL4A5 into pIRES-hrGFP-2a 
 In order to transfer the COL4A5 cDNA into a mammalian expression vector, it 
was removed from the Blue Heron pUC-minus vector using a double digested with NotI 
and SalI (Promega Corporation, Madison, WI) in a 20µl reaction with final 
concentrations of 1X Buffer D, 0.2µg Bovine Serum Albumin and 5U of each enzyme. 
The plasmids were digested at 37˚C for one hour followed by a 65˚ incubation for 15 
minutes and the products resolved on an agarose gel. The mammalian expression vector, 
pIRES-hrGFP-2a, was similarly digested. The digestion products were resolved on a 1% 
agarose gel, the bands corresponding to the COL4A5 insert and the pIRES-hrGFP-2a 
(Stratagene, La Jolla, CA) linear plasmid were cut out and gel extracted using the 
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QIAquick Gel Extraction kit (Qiagen, Valencia, CA). The COL4A5 and linear pIRES-
hrGFP-2a gel extraction products were ligated together following the NEB Quick Ligase 
manufacturer’s protocol (New England Biolabs, Ipswich, MA) and incubated at room 
temperature for one hour. Two microliters of each ligations was transformed into 
SURE® cells (Stratagene).   
 
 
 
 
Fig. 4.1. Wild-type and modified COL4A5 genes. The vertical lines represent 
interruptions in the collagenous domain of the coding sequence. The modified COL4A5 
gene has a FLAG amino acid sequence inserted into the fifth interruption. In addition, it 
has four unique restriction sites (two on the 5′ and two on the 3′ ends): NotI site in blue, 
SacII site in yellow, SphI site in green and SalI site in orange.   
 
 
 
 The transformants were grown on LB plates containing 0.05g/L of Ampicillin. 
Colonies were picked and cultured overnight and plasmids isolated using the Eppendorf 
Plasmid Mini Kit (Eppendorf, Westbury, NY). Single digests of the plasmids were 
7S NC1
IPRPGTGITI
7S NC1
IPRDYKDDDKITI 
Wild type 
COL4A5 
Modified 
COL4A5 
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performed with NotI and SalI in 20µl reactions with final concentrations of 1X Buffer D, 
0.2µg Bovine Serum Albumin and 5U of enzyme (Promega). The plasmids were 
digested at 37˚C for one hour followed by a 65˚ incubation for 15 minutes and the 
products resolved on a 1.2% agarose gel. Double digest with both NotI and SalI were 
performed as previously described (Promega). The products were run on a 1.2% agarose 
gel along with undigested plasmids. The resulting plasmids that were suspected to have 
the COL4A5 insert were subjected to a second set of single digests using BglII and 
HindIII in 20µl reactions with final concentrations of 1X Buffer B, 0.2µg Bovine Serum 
Albumin and 5U of enzyme (Promega Corp.). Double digests were performed using both 
BglII and HindIII in 20µl reactions with 1X Buffer B, 0.2µg Bovine Serum Albumin and 
5U of each enzyme (Promega Corp.). Products were resolved on 1.2% agarose gels.   
 
Transfer of COL4A5 into pcDNA3.1/CT-GFP-TOPO 
 The COL4A5 cDNA will be transferred into the pcDNA3.1/CT-GFP-TOPO 
mammalian expression vector (Invitrogen, Carlsbad, CA). The entire COL4A5 insert was 
amplified from the Blue Heron pUCminus vector using the following primers: Forward 
5'-CATGGCGGCCGCGCGGCACAAACTCAAGATT-3', Reverse 5'-
GAGAGCGGCCGCGGCTACAGTCAGTGGAGAGGA-3'. Amplification was 
performed using the Advantage GC Genomic LA Polymerase kit (Clontech, Mountain 
View, CA) following the manufacturer’s protocol with 100ng of plasmid DNA. 
Reactions conditions are as follows: 95˚ for five minutes, 56˚ for 30 seconds, 72˚ for six 
minutes followed by 35 cycles of 95˚ for one minute, 71˚ for 30 seconds and 72˚ for six 
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minutes. The products were resolved on a 1% agarose gel and gel extracted using the 
Qiagen Qiaex II Gel Extraction Kit (Qiagen Inc.). Thirty ng of the gel extraction 
products were then ligated into pcDNA3.1/CT-GFP-TOPO following the manufacturer’s 
protocol and incubated at room temperature for one hour. Two µl of the ligation mixture 
was then transformed into Escherichia coli TOP10 cells (Invitrogen). Additionally, 
ligations into pcDNA3.1/CT-GFP-TOPO were transformed into E. coli EC100 
chemically competent cells (Epicentre) following the suggested protocol. Plasmids were 
isolated from the resulting colonies using the laboratory STE protocol. The plasmids 
were screened for the COL4A5 insert by PCR amplification using the above described 
primers and conditions. 
 Plasmids for which positive amplification of COL4A5 was detected were 
sequenced using the Big Dye Terminator v 1.1 Cycle Sequencing Kit (Applied 
Biosystems, Foster City, CA) using following protocol: 3µl plasmid, 2µl of Big Dye v. 
1.1 and 1µl of the appropriate primer. Two of the primers (T7 forward and GFP reverse) 
used for sequencing were provided by Invitrogen, the third was designed to capture the 
internal portion of the COL4A5 cDNA: Forward 5'-GTCATCACTGCCAGGACC-3'. 
The sequencing reaction used was as follows: 96˚ for two mintues followed by 30 cycles 
of 96˚ for 30 seconds, 55˚ for 15 seconds and 60˚ for four minutes.  
 
Transfections  
 HEK293 cells were maintained using E-MEM media from ATCC (ATCC, 
Manassas, VA) supplemented with 10% FBS (Invitrogen), 100U of Penicillin and 100ug 
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of Streptomycin (Invitrogen). 500,000 cells were pre-plated in each well of a six well 
plate and allowed to adhere and grow for 24 hours prior to transfection. Cells were 
transiently transfected using 7.5µl Lipofectamine 2000 (Invitrogen) in each well of a six 
well plate. Plasmid DNA concentrations varied from 6.0µg of the control vector (pIRES-
hrGPF-2a) to 8.0µg of the pIRES-hrGFP-2a with COL4A5 insert. The media was 
replaced five to six hours post-transfection. Transfection efficiency was estimated by 
visual analysis of GFP expression 24 and 48 hours post-transfection. 
 
Results and discussion 
 The synthesized COL4A5 cDNA was confirmed by sequencing performed by 
Blue Heron Biotechnologies. The cDNA can be transferred into various vectors using 
restriction digestion that assures directional cloning. This method was used to transfer 
the COL4A5 cDNA into pIRES-hrGFP-2a. Verification of transfer into this vector was 
performed by restriction digestion and all resulting products were of the expected sizes. 
 The FLAG sequence inserted into the fifth collagenous interruption will be used 
to distinguish the introduced α5(IV) from native α5(IV). Although XLHN-affected male 
NAV dogs will not produce α5(IV), these dogs will not be used for initial transfer 
experiments. Initially, in vitro expression studies in HEK293 cells will be performed, 
and the α5(IV) protein will be detected by western blotting with a FLAG antibody. Once 
we have verified that the cDNA does encode a α5(IV) protein of the correct size, in vivo 
efforts to transfer the cDNA into the kidneys of XLHN-carrier female NAV dogs will be 
undertaken. The carrier females have both a wild-type and mutated copy of COL4A5 and 
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thus, the introduced α5(IV) will need to be distinguished from the wild-type protein. The 
insertion of this epitope did not alter the reading frame. Figure 4.2 shows the alignment 
of the amino acid sequences, they are identical except for the FLAG epitope. 
 
 
 
COLW  MKLRGVSLAAGWFLLALSLWGQPAEAAACYGCSPGSKCDCSGVKGEKGERGFPGLEGHPG 60 
COLM  MKLRGVSLAAGWFLLALSLWGQPAEAAACYGCSPGSKCDCSGVKGEKGERGFPGLEGHPG 60 
      ************************************************************ 
 
COLW  LPGFPGPEGPPGPRGQKGDDGIRGPPGPKGIRGPPGLPGFPGTPGLPGMPGHDGAPGPQG 120 
COLM  LPGFPGPEGPPGPRGQKGDDGIRGPPGPKGIRGPPGLPGFPGTPGLPGMPGHDGAPGPQG 120 
      ************************************************************ 
 
COLW  IPGCNGTKGERGFPGSPGFPGLEGPPGPPGIPGMKGEPGSIIMSSLPGPKGNPGYPGPPG 180 
COLM  IPGCNGTKGERGFPGSPGFPGLEGPPGPPGIPGMKGEPGSIIMSSLPGPKGNPGYPGPPG 180 
      ************************************************************ 
 
COLW  IQGPAGPTGLPGPIGPPGPPGLMGPPGPPGLPGPKGNMGLNFQGPKGEKGEQGLQGPPGP 240 
COLM  IQGPAGPTGLPGPIGPPGPPGLMGPPGPPGLPGPKGNMGLNFQGPKGEKGEQGLQGPPGP 240 
      ************************************************************ 
 
COLW  PGQISEQKRPIDVEFQKGDQGLPGDRGPPGPPGIRGPPGPPGGMKGEKGEQGEPGKRGKP 300 
COLM  PGQISEQKRPIDVEFQKGDQGLPGDRGPPGPPGIRGPPGPPGGMKGEKGEQGEPGKRGKP 300 
      ************************************************************ 
 
COLW  GKDGENGQPGIPGLPGDPGYPGEPGRDGEKGQKGDIGSTGPPGLVIPRPGTG----VTVG 356 
COLM  GKDGENGQPGIPGLPGDPGYPGEPGRDGEKGQKGDIGSTGPPGLVIPRDYKDDDDKVTVG 360 
      ************************************************        **** 
 
COLW  EKGNMGLPGLPGEKGERGFPGIQGPPGLPGPPGTAVMGPPGPPGFPGERGQKGDEGPPGI 416 
COLM  EKGNMGLPGLPGEKGERGFPGIQGPPGLPGPPGTAVMGPPGPPGFPGERGQKGDEGPPGI 420 
      ************************************************************ 
 
COLW  SIPGFPGLDGQPGAPGLRGPPGPPGPHISPSDEICETGPPGPPGSPGDRGLQGEQGVKGD 476 
COLM  SIPGFPGLDGQPGAPGLRGPPGPPGPHISPSDEICETGPPGPPGSPGDRGLQGEQGVKGD 480 
      ************************************************************ 
 
COLW  KGDTCFNCIGTGVSGPRGQPGLPGLPGPPGSLGFPGQKGEKGHAGLTGPKGLTGIPGAPG 536 
COLM  KGDTCFNCIGTGVSGPRGQPGLPGLPGPPGSLGFPGQKGEKGHAGLTGPKGLTGIPGAPG 540 
      ************************************************************ 
 
COLW  PPGFPGSKGEPGDVLTFPGMKGDKGELGYPGAPGLPGLPGTPGQDGLPGLPGPKGEPGGI 596 
COLM  PPGFPGSKGEPGDVLTFPGMKGDKGELGYPGAPGLPGLPGTPGQDGLPGLPGPKGEPGGI 600 
      ************************************************************ 
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Fig. 4.2. Continued  
 
COLW  AFKGERGPPGNPGLPGLPGNRGPMGPVGFGPPGPVGEKGIQGVAGNPGQPGIPGPKGDPG 656 
COLM  AFKGERGPPGNPGLPGLPGNRGPMGPVGFGPPGPVGEKGIQGVAGNPGQPGIPGPKGDPG 660 
      ************************************************************ 
 
COLW  QTITQPGKPGLPGNPGRHGEVGLPGDPGLPGPPGLPGIPGNKGEPGIPGIGLPGPPGPKG 716 
COLM  QTITQPGKPGLPGNPGRHGEVGLPGDPGLPGPPGLPGIPGNKGEPGIPGIGLPGPPGPKG 720 
      ************************************************************ 
 
COLW  FPGIQGPPGAPGTPGRIGLEGPSGPPGFPGPKGEPGLGLPGPPGPPGLPGFKGTLGPKGD 776 
COLM  FPGIQGPPGAPGTPGRIGLEGPSGPPGFPGPKGEPGLGLPGPPGPPGLPGFKGTLGPKGD 780 
      ************************************************************ 
 
COLW  RGFPGPPGLPGRTGLDGLPGPKGDVGPKGQPGPMGPPGLPGIGVQGPPGPPGIPGPVGEP 836 
COLM  RGFPGPPGLPGRTGLDGLPGPKGDVGPKGQPGPMGPPGLPGIGVQGPPGPPGIPGPVGEP 840 
      ************************************************************ 
 
COLW  GLHGIPGEKGDPGPPGFDVLGPPGERGSPGIPGAPGPMGPPGTPGLPGKAGASGFPGAKG 896 
COLM  GLHGIPGEKGDPGPPGFDVLGPPGERGSPGIPGAPGPMGPPGTPGLPGKAGASGFPGAKG 900 
      ************************************************************ 
 
COLW  EMGMMGPPGPPGPLGIPGRSGVPGLKGDNGLQGQPGPPGPEGEKGGKGEPGLPGPPGPVD 956 
COLM  EMGMMGPPGPPGPLGIPGRSGVPGLKGDNGLQGQPGPPGPEGEKGGKGEPGLPGPPGPVD 960 
      ************************************************************ 
 
COLW  PDLLGSKGEKGDPGLPGIPGVSGPKGYQGLPGDPGQPGLSGQPGLPGPSGPKGNPGLPGK 1016 
COLM  PDLLGSKGEKGDPGLPGIPGVSGPKGYQGLPGDPGQPGLSGQPGLPGPSGPKGNPGLPGK 1020 
      ************************************************************ 
 
COLW  PGLTGPPGLKGSIGDMGFPGPQGVKGSPGPPGVPGQPGSPGLPGQKGEKGDPGVSGIGLP 1076 
COLM  PGLTGPPGLKGSIGDMGFPGPQGVKGSPGPPGVPGQPGSPGLPGQKGEKGDPGVSGIGLP 1080 
      ************************************************************ 
 
COLW  GLPGPKGEAGLPGYPGNPGIKGSMGDTGLPGLPGTPGAKGQPGLPGFPGTPGLPGPKGIN 1136 
COLM  GLPGPKGEAGLPGYPGNPGIKGSMGDTGLPGLPGTPGAKGQPGLPGFPGTPGLPGPKGIN 1140 
      ************************************************************ 
 
COLW  GPPGNPGLPGEPGPVGGGGRPGPPGPPGEKGNPGQDGIPGPAGQKGEPGQPGFGIPGPPG 1196 
COLM  GPPGNPGLPGEPGPVGGGGRPGPPGPPGEKGNPGQDGIPGPAGQKGEPGQPGFGIPGPPG 1200 
      ************************************************************ 
 
COLW  LPGLSGQKGDGGLPGIPGNPGLPGPKGEPGFQGFPGVQGPPGPPGSPGPALEGPKGNPGP 1256 
COLM  LPGLSGQKGDGGLPGIPGNPGLPGPKGEPGFQGFPGVQGPPGPPGSPGPALEGPKGNPGP 1260 
      ************************************************************ 
 
COLW  QGPPGRPGPTGFQGLPGPEGPRGLPGNGGIKGERGNPGQPGQPGLPGLKGDQGPPGIQGN 1316 
COLM  QGPPGRPGPTGFQGLPGPEGPRGLPGNGGIKGERGNPGQPGQPGLPGLKGDQGPPGIQGN 1320 
      ************************************************************ 
 
COLW  PGRPGLNGMKGDPGLPGVPGFPGMKGPSGVPGSAGPEGDPGLVGPPGPPGLPGPSGQSII 1376 
COLM  PGRPGLNGMKGDPGLPGVPGFPGMKGPSGVPGSAGPEGDPGLVGPPGPPGLPGPSGQSII 1380 
      ************************************************************ 
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Fig. 4.2. Continued 
 
COLW  IKGDVGPPGIPGQPGLKGLPGLPGPQGLPGPIGPPGDPGRNGLPGFDGAGGRKGDPGLPG 1436 
COLM  IKGDVGPPGIPGQPGLKGLPGLPGPQGLPGPIGPPGDPGRNGLPGFDGAGGRKGDPGLPG 1440 
      ************************************************************ 
 
COLW  QPGTRGLDGPPGPDGMQGPPGPPGTSSIAHGFLITRHSQTTDAPQCPHGTVQIYEGFSLL 1496 
COLM  QPGTRGLDGPPGPDGMQGPPGPPGTSSIAHGFLITRHSQTTDAPQCPHGTVQIYEGFSLL 1500 
      ************************************************************ 
 
COLW  YVQGNKRAHGQDLGTAGSCLRRFSTMPFMFCNINNVCNFASRNDYSYWLSTPEPMPMSME 1556 
COLM  YVQGNKRAHGQDLGTAGSCLRRFSTMPFMFCNINNVCNFASRNDYSYWLSTPEPMPMSME 1560 
      ************************************************************ 
 
COLW  PLKGQSIQPFISRCAVCEAPAVVIAVHSQTIQIPHCPHGWDSLWIGYSFMMHTSAGAEGS 1616 
COLM  PLKGQSIQPFISRCAVCEAPAVVIAVHSQTIQIPHCPHGWDSLWIGYSFMMHTSAGAEGS 1620 
      ************************************************************ 
 
COLW  GQALASPGSCLEEFRSAPFIECHGRGTCNYYANSYSFWLATVDVSDMFSKPQSETLKAGD 1676 
COLM  GQALASPGSCLEEFRSAPFIECHGRGTCNYYANSYSFWLATVDVSDMFSKPQSETLKAGD 1680 
      ************************************************************ 
 
COLW  LRTRISRCQVCMKRT 1691 
COLM  LRTRISRCQVCMKRT 1695 
      *************** 
 
Fig. 4.2. Comparison of the wild-type (COLW) and modified (COLM) COL4A5 amino 
acid sequences. The FLAG epitope is highlighted in yellow. 
 
 
  
 Unfortunately, once the cDNA was transferred into the pIRES-hrGFP-2a 
mammalian expression vector and used for transfection into HEK293 cells, no GFP was 
detected (efficiency was <1%). The absence of detectable GFP indicates a failure to 
express the α5(IV) protein. Further transfection experiments demonstrated that even the 
empty pIRES-hrGPF-2a vector was not capable of driving expression of the GFP 
marker; transfection efficiency was <1%. The fact that the empty vector was not 
sufficiently strong enough to produce GFP led to a search for an alternate vector. 
 The Invitrogen pcDNA3.1/CT-GFP-TOPO vector was chosen because of its 
previously described use in the in vitro expression of a canine COL4A5 cDNA (Harvey 
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et al., 2003). Efforts to insert the synthetic COL4A5 cDNA into this vector have not 
produced the desired results. Initial attempts were made using the TOP10 cells provided 
by Invitrogen. These cells, however, do not seem to be sufficiently inert with respect to 
genetic recombination. That is, all of the COL4A5 inserts have been significantly shorter 
than expected indicating significant rearrangement. When the inserts were amplified, 
product sizes were only 1.1Kb, opposed to the expected full length 5.3Kb. Sequencing of 
the inserts confirmed the presence of only the first 1080 bp of the COL4A5 cDNA (Fig. 
4.3)     
 
 
COL  -------------CACAAACTCAAGATTATGAAACTGCGTGGAGTCAGCCTGGCTGCCGG 47 
A    GGCGGCCGCGCGGCACAAACTCAAGATTATGAAACTGCGTGGAGTCAGCCTGGCTGCCGG 60 
B    GGCGGCCGCGCGGCACAAACTCAAGATTATGAAACTGCGTGGAGTCAGCCTGGCTGCCGG 60 
C    GGCGGCCGCGCGGCACAAACTCAAGATTATGAAACTGCGTGGAGTCAGCCTGGCTGCCGG 60 
D    -------------CACAAACTCAAGATTATGAAACTGCGTGGAGTCAGCCTGGCTGCCGG 47 
                  *********************************************** 
 
COL  CTGGTTCTTACTGGCCCTGAGTCTTTGGGGGCAGCCCGCAGAGGCTGCGGCTTGCTATGG 107 
A    CTGGTTCTTACTGGCCCTGAGTCTTTGGGGGCAGCCCGCAGAGGCTGCGGCTTGCTATGG 120 
B    CTGGTTCTTACTGGCCCTGAGTCTTTGGGGGCAGCCCGCAGAGGCTGCGGCTTGCTATGG 120 
C    CTGGTTCTTACTGGCCCTGAGTCTTTGGGGGCAGCCCGCAGAGGCTGCGGCTTGCTATGG 120 
D    CTGGTTCTTACTGGCCCTGAGTCTTTGGGGGCAGCCCGCAGAGGCTGCGGCTTGCTATGG 107 
     ************************************************************ 
 
COL  GTGTTCTCCAGGATCAAAATGTGACTGTAGTGGTGTAAAAGGAGAAAAGGGGGAGAGAGG 167 
A    GTGTTCTCCAGGATCAAAATGTGACTGTAGTGGTGTAAAAGGAGAAAAGGGGGAGAGAGG 180 
B    GTGTTCTCCAGGATCAAAATGTGACTGTAGTGGTGTAAAAGGAGAAAAGGGGGAGAGAGG 180 
C    GTGTTCTCCAGGATCAAAATGTGACTGTAGTGGTGTAAAAGGAGAAAAGGGGGAGAGAGG 180 
D    GTGTTCTCCAGGATCAAAATGTGACTGTAGTGGTGTAAAAGGAGAAAAGGGGGAGAGAGG 167 
     ************************************************************ 
 
COL  ATTTCCGGGTTTGGAAGGCCATCCAGGTTTGCCTGGATTTCCAGGTCCAGAAGGGCCTCC 227 
A    ATTTCCGGGTTTGGAAGGCCATCCAGGTTTGCCTGGATTTCCAGGTCCAGAAGGGCCTCC 240 
B    ATTTCCGGGTTTGGAAGGCCATCCAGGTTTGCCTGGATTTCCAGGTCCAGAAGGGCCTCC 240 
C    ATTTCCGGGTTTGGAAGGCCATCCAGGTTTGCCTGGATTTCCAGGTCCAGAAGGGCCTCC 240 
D    ATTTCCGGGTTTGGAAGGCCATCCAGGTTTGCCTGGATTTCCAGGTCCAGAAGGGCCTCC 227 
     ************************************************************ 
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Fig. 4.3. Continued 
 
COL  AGGGCCTCGGGGACAAAAGGGTGATGATGGAATTCGAGGGCCACCAGGACCAAAAGGGAT 287 
A    AGGGCCTCGGGGACAAAAGGGTGATGATGGAATTCGAGGGCCACCAGGACCAAAAGGGAT 300 
B    AGGGCCTCGGGGACAAAAGGGTGATGATGGAATTCGAGGGCCACCAGGACCAAAAGGGAT 300 
C    AGGGCCTCGGGGACAAAAGGGTGATGATGGAATTCGAGGGCCACCAGGACCAAAAGGGAT 300 
D    AGGGCCTCGGGGACAAAAGGGTGATGATGGAATTCGAGGGCCACCAGGACCAAAAGGGAT 287 
     ************************************************************ 
 
COL  CAGAGGTCCTCCTGGACTTCCTGGATTTCCAGGGACACCGGGTCTTCCTGGAATGCCAGG 347 
A    CAGAGGTCCTCCTGGACTTCCTGGATTTCCAGGGACACCGGGTCTTCCTGGAATGCCAGG 360 
B    CAGAGGTCCTCCTGGACTTCCTGGATTTCCAGGGACACCGGGTCTTCCTGGAATGCCAGG 360 
C    CAGAGGTCCTCCTGGACTTCCTGGATTTCCAGGGACACCGGGTCTTCCTGGAATGCCAGG 360 
D    CAGAGGTCCTCCTGGACTTCCTGGATTTCCAGGGACACCGGGTCTTCCTGGAATGCCAGA 347 
     ***********************************************************  
 
COL  CCATGATGGGGCCCCAGGACCTCAAGGTATCCCTGGATGCAATGGAACCAAGGGAGAACG 407 
A    CCATGATGGGGCCCCAGGACCTCAAGGTATCCCTGGATGCAATGGAACCAAGGGAGAACG 420 
B    CCATGATGGGGCCCCAGGACCTCAAGGTATCCCTGGATGCAATGGAACCAAGGGAGAACG 420 
C    CCATGATGGGGCCCCAGGACCTCAAGGTATCCCTGGATGCAATGGAACCAAGGGAGAACG 420 
D    CCATGATGGGGCCCCAGGACCTCAAGGTATCCCTGGATGCAATGGAACCAAGGGAGAACG 407 
     ************************************************************ 
 
COL  TGGATTTCCAGGCAGTCCTGGTTTTCCTGGTCTAGAGGGTCCTCCGGGACCTCCTGGGAT 467 
A    TGGATTTCCAGGCAGTCCTGGTTTTCCTGGTCTAGAGGGTCCTCCGGGACCTCCTGGGAT 480 
B    TGGATTTCCAGGCAGTCCTGGTTTTCCTGGTCTAGAGGGTCCTCCGGGACCTCCTGGGAT 480 
C    TGGATTTCCAGGCAGTCCTGGTTTTCCTGGTCTAGAGGGTCCTCCGGGACCTCCTGGGAT 480 
D    TGGATTTCCAGGCAGTCCTGGTTTTCCTGGTCTAGAGGGTCCTCCGGGACCTCCTGGGAT 467 
     ************************************************************ 
 
COL  CCCAGGTATGAAGGGAGAACCAGGTAGTATAATTATGTCATCACTGCCAGGACCAAAGGG 527 
A    CCCAGGTATGAAGGGAGAACCAGGTAGTATAATTATGTCATCACTGCCAGGACCAAAGGG 540 
B    CCCAGGTATGAAGGGAGAACCAGGTAGTATAATTATGTCATCACTGCCAGGACCAAAGGG 538 
C    CCCAGGTATGAAGGGAGAACCAGGTAGTATAATTATGTCATCACTGCCAGGACCAAAGGG 540 
D    CCCAGGTATGAAGGGAGAACCAGGTAGTATAATTATGTCATCACTGCCAGGACCAAAGGG 527 
     ************************************************************ 
 
COL  TAATCCAGGATATCCAGGTCCTCCTGGAATACAAGGCCCAGCTGGTCCCACTGGTTTACC 587 
A    TAATCCAGGATATCCAGGTCCTCCTGGAATACAAGGCCCAGCTGGTCCCACTGGTTTACC 600 
B    TAATCCAGGATATCCAGGTCCTCCTGGAATACAAGGCCCAGCTGGTCCCACTGGTTTACC 596 
C    TAATCCAGGATATCCAGGTCCTCCTGGAATACAAGGCCCAGCTGGTCCCACTGGTTTACC 600 
D    TAATCCAGGATATCCAGGTCCTCCTGGAATACAAGGCCCAGCTGGTCCCACTGGTTTACC 587 
     ************************************************************ 
 
COL  AGGGCCAATTGGTCCCCCAGGACCACCTGGTTTGATGGGCCCTCCTGGTCCACCAGGACT 647 
A    AGGGCCAATTGGTCCCCCAGGACCACCTGGTTTGATGGGCCCTCCTGGTCCACCAGGACT 660 
B    AGGGCCAATTGGTCCCCCAGGACCACCTGGTTTGATGGGCCCTCCTGGTCCACCAGGACT 656 
C    AGGGCCAATTGGTCCCCCAGGACCACCTGGTTTGATGGGCCCTCCTGGTCCACCAGGACT 660 
D    AGGGCCAATTGGTCCCCCAGGACCACCTGGTTTGATGGGCCCTCCTGGTCCACCAGGACT 647 
     ************************************************************ 
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Fig. 4.3. Continued 
 
COL  TCCAGGACCAAAGGGGAATATGGGCTTAAATTTCCAGGGACCCAAAGGTGAAAAAGGTGA 707 
A    TCCAGGACCAAAGGGGAATATGGGCTTTAATTTCCAGGGACCCAAAGGTGAAAAAGGTGA 720 
B    TCCAGGACCAAAGGGGAATATGGGCTTAAATTTCCAGGGACCCAAAGGTGAAAAAGGTGA 716 
C    TCCAGGACCAAAGGGGAATATGGGCTTAAATTTCCAGGGACCCAAAGGTGAAAAAGGTGA 720 
D    TCCAGGACCAAAGGGGAATATGGGCTTAAATTTCCAGGGACCCAAAGGTGAAAAAGGTGA 707 
     *************************** ******************************** 
  
COL  GCAAGGTCTTCAGGGTCCCCCTGGTCCTCCTGGGCAGATCAGTGAACAGAAAAGACCAAT 767 
A    GCAAGGTCTTCAGGGTCCCCCTGGTCCTCCTGGGCAGATCAGTGAACAGAAAAGACCAAT 780 
B    GCAAGGTCTTCAGGGTCCCCCTGGTCCTCCTGGGCAGATCAGTGAACAGAAAAGACCAAT 776 
C    GCAAGGTCTTCAGGGTCCCCCTGGTCCTCCTGGGCAGATCAGTGAACAGAAAAGACCAAT 780 
D    GCAAGGTCTTCAGGGTCCCCCTGGTCCTCCTGGGCAGATCAGTGAACAGAAAAGACCAAT 767 
     ************************************************************ 
 
COL  TGATGTAGAGTTTCAGAAAGGAGATCAGGGACTTCCTGGTGACCGAGGGCCTCCTGGACC 827 
A    TGATGTAGAGTTTCAGAAAGGAGATCAGGGACTTCCTGGTGACCGAGGGCCTCCTGGACC 840 
B    TGATGTAGAGTTTCAGAAAGGAGATCAGGGACTTCCTGGTGACCGAGGGCCTCCTGGACC 836 
C    TGATGTAGAGTTTCAGAAAGGAGATCAGGGACTTCCTGGTGACCGAGGGCCTCCTGGACC 840 
D    TGATGTAGAGTTTCAGAAAGGAGATCAGGGACTTCCTGGTGACCGAGGGCCTCCTGGACC 827 
     ************************************************************ 
 
COL  TCCAGGGATACGTGGTCCTCCAGGTCCTCCAGGTGGTATGAAAGGTGAGAAGGGTGAACA 887 
A    TCCAGGGATACGTGGTCCTCCAGGTCCTCCAGGTGGTATGAAAGGTGAGAAGGGTGAACA 900 
B    TCCAGGGATACGTGGTCCTCCAGGTCCTCCAGGTGGTATGAAAGGTGAGAAGGGTGAACA 896 
C    TCCAGGGATACGTGGTCCTCCAGGTCCTCCAGGTGGTATGAAAGGTGAGAAGGGTGAACA 900 
D    TCCAGGGATACGTGGTCCTCCAGGTCCTCCAGGTGGTATGAAAGGTGAGAAGGGTGAACA 887 
     ************************************************************ 
 
COL  AGGAGAGCCAGGCAAAAGAGGTAAACCGGGCAAAGATGGAGAGAATGGCCAACCAGGAAT 947 
A    AGGAGAGCCAGGCAAAAGAGGTAAACCGGGCAAAGATGGAGAGAATGGCCAACCAGGAAT 960 
B    AGGAGAGCCAGGCAAAAGAGGTAAACCGGGCAAAGATGGAGAGAATGGCCAACCAGGAAT 956 
C    AGGAGAGCCAGGCAAAAGAGGTAAACCGGGCAAAGATGGAGAGAATGGCCAACCAGGAAT 960 
D    AGGAGAGCCAGGCAAAAGAGGTAAACCGGGCAAAGATGGAGAGAATGGCCAACCAGGAAT 947 
     ************************************************************ 
 
COL  TCCAGGTTTACCTGGTGATCCTGGTTACCCTGGTGAACCAGGAAGGGATGGAGAAAAGGG 1007 
A    TCCAGGTTTACCTGGTGATCCTGGTTACCCTGGTGAACCAGGAAGGGATGGAGAAAAGGG 1020 
B    TCCAGGTTTACCTGGTGATCCTGGTTACCCTGGTGAACCAGGAAGGGATGGAGAAAAGGG 1016 
C    TCCAGGTTTACCTGGTGATCCTGGTTACCCTGGTGAACCAGGAAGGGATGGAGAAAAGGG 1020 
D    TCCAGGTTTACCTGGTGATCCTGGTTACCCTGGTGAACCAGGAAGGGATGGAGAAAAGGG 1007 
     ************************************************************ 
 
COL  CCAAAAAGGTGACATTGGCTCAACTGGGCCTCCTGGACTTGTAATTCCTAGGGACTACAA 1067 
A    CCAAAAAGGTGACATTGGCTCAACTGGGCCTCCTGGACTTGTAATTCCTAGGGACTACAA 1080 
B    CCAAAAAGGTGACATTGGCTCAACTGGGCCTCCTGGACTTGTAATTCCTAGGGACTACAA 1076 
C    CCAAAAAGGTGACATTGGCTCAACTGGGCCTCCTGGACTTGTAATTCCTAGGGACTACAA 1080 
D    CCAAAAAGGTGACATTGGCTCAACTGGGCCTCCTGGACTTGTAATTCCTAGGGACTACAA 1067 
     ************************************************************ 
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Fig. 4.3. Continued 
 
COL  GGACGACGACGACAAGGTAACTGTAGGAGAGAAAGGAAACATGGGGTTACCTGGCTTGCC 1127 
A    GGACGACGACGACAAGGTAACTGTAGGAGAGAAAGG---AAATATGGGGTTACCTGAGAC 1137 
B    GGACGACGACGACAAGGTAACTGTAGGAGAGAAAGG---AAATATGGGGTTACCTGAGAC 1133 
C    GGACGACGACGACAAGGTAACTGTAGGAGAGAAAGG---AAATATGGGGTTACCTGAGAC 1137 
D    GGACGACGACGAC----TAATCTTGAGTTTGTGCCG---CGGGCGGCCGCTCGTTGAGAC 1120 
     *************    ***   *  *   *    *         *           * * 
 
Fig. 4.3. Alignment of sequences from Top10 cells to COL4A5. Four plasmid sequences 
(A, B, C and D) have been aligned to COL4A5 (abbreviated COL). The alignments 
match perfectly until base 1080 of COL4A5. The start codons are highlighted in yellow.  
 
 
 
 Due to the above problems with TOP10 cells, EC100 cells were chosen for 
subsequent use. These cells were used by Blue Heron Biotechnologies to propagate the 
original of pUCminus vector with the COL4A5 insert, and therefore should work for the 
transfer into pcDNA3.1/CT-GFP-TOPO. After the full length cDNA has been inserted 
into this vector, further in vitro expression studies will be conducted to ensure that the 
protein is properly made.  
 Although this work has been hindered by some difficulties, this is often the case 
when working with a collagen gene. These genes are large complex, and expression of 
the protein is often difficult to optimize in in vitro experiments. However, because of the 
precedents set by other groups (Heikkila et al., 2001; Harvey et al., 2003), we are 
confident that our goal to produce a functional COL4A5 cDNA that is suitable for in vivo 
gene transfer experiments can be achieved.  
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CHAPTER V 
 
ANALYSIS OF TYPE IV COLLAGEN GENE EXPRESSION IN AUTOSOMAL 
RECESSIVE AND X-LINKED FORMS OF HEREDITARY NEPHROPATHY IN 
THE ENGLISH COCKER SPANIEL AND MIXED BREED DOG 
Overview 
 
AS and HN refer to hereditary glomerular nephropathies caused by mutations in 
type IV collagen genes. These diseases occur in the human (AS) and various breeds of 
the domestic dog (HN). Among dogs, a mixed breed kindred, termed NAV dogs, has 
XLHN due to a mutation in COL4A5. Additionally, the ECS has ARHN caused by an 
uncharacterized mutation in either COL4A3 or COL4A4. To assess type IV collagen 
mRNA levels in kidneys of such dogs, RNA was isolated from renal cortex and 
examined by real time quantitative RT-PCR (qRT-PCR). This was done for (1) normal 
NAV male, XLHN-affected NAV male and XLHN-carrier female NAV dogs, (2) 
ARHN-affected ECS and (3) control dogs, all lacking signs of renal diseases, 
representing four other breeds. XLHN-affected NAV dogs exhibited a greater than two 
fold reduction in COL4A2 and COL4A5 mRNA levels (P=0.13 and 0.03, respectively). 
XLHN-carrier female NAV dogs exhibited a greater than two reduction in COL4A4 and 
COL4A5 mRNA levels (P=0.03 and 0.06, respectively). ARHN-affected ECS exhibited 
a greater than two fold reduction in COL4A4 and COL4A6 mRNA levels (P=0.13 and 
0.36, respectively). Importantly, for COL4A5, the gene causative for XLHN, there was a 
reduced level of mRNA in XLHN-affected and carrier NAV dogs. This pattern was 
mimicked to a lesser extent in ARHN-affected ECS COL4A4 mRNA levels. Given the 
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similar patterns of COL4A5 and COL4A4 mRNA levels in the respective affected dogs, 
it is likely that a mutation in COL4A4 is causative for ARHN in the ECS. 
 
Introduction 
AS and HN refer to progressive hereditary glomerular nephropathies caused by 
mutations in three members of the type IV collagen gene family that encode proteins 
required for normal GBM structure and function. These conditions occur in the human 
(AS) and various breeds of the domestic dog (HN) and are transmitted in X-linked, 
autosomal recessive and autosomal dominant fashions.  
XLHN has been identified in two families of the dog: 1) a Samoyed kindred and 
2) a kindred of a mixed breed dogs, the NAV dogs (Bernards and Valli, 1977; Lees et 
al., 1999). In the Samoyed model of XLHN, the causative mutation is a single base 
substitution in exon 35 of COL4A5, which results in a stop codon (Zheng et al., 1994). 
The causative mutation in NAV dogs is a ten base pair deletion in exon nine of COL4A5 
(Cox et al., 2003). ARHN occurs in the English Cocker Spaniel (ECS). The mutation 
causative for ARHN in the ECS is unknown, but is suspected to be in either COL4A3 or 
COL4A4, as in human ARAS (Mochizuki et al., 1994; van der Loop et al., 2000; Longo 
et al., 2002).  
Characterization of differences in transcript levels that occur in these two canine 
models of HN will enhance our understanding of the disease processes. Although mRNA 
profiles in other animal models of HN have been reported, no previous studies have 
utilized qRT-PCR. Through the use of qRT-PCR, we identified differences in mRNA 
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levels of the type IV collagen genes of XLHN-affected, XLHN-carrier and ARHN-
affected dogs, compared with dogs having no signs of renal disease. These data suggest 
that COL4A4 is the gene causative for ARHN in the ECS. 
   
Materials and methods 
Animals 
The NAV dogs used in this study were members of a colony maintained at Texas 
A&M University. Status of normal and XLHN-affected NAV dogs was determined by 
genotype using primers designed to amplify the region harboring the ten base pair 
deletion in COL4A5 (Forward 5′-CGCTTGACTATTTTGTGTGTCATAA-3′, Reverse 
5′-AAGGTGATGCTGTGATCTGATTTA-3′). However, the XLHN-carrier female 
NAV dogs were born prior to implementation of this test (however, one could do the 
PCR test on these dogs as well), and the status of these dogs was determined by IF 
staining of their epidermal basement membranes, as previously described (Lees et al., 
1999). XLHN-affected dogs were necropsied between eight and ten months of age, when 
their serum creatinine levels were ≥ 5.0 mg/dL. During necropsy whole kidneys were 
harvested and renal cortex isolated. Normal NAV dogs were euthanized, whole kidneys 
harvested and renal cortex isolated, at eight and 15 months of age. XLHN-carrier female 
NAV dogs were euthanized (for reasons unrelated to HN) and necropsied between 13 
months and seven years of age. Whole kidneys were harvested and renal cortex isolated 
from the XLHN-carrier females in an identical fashion to the normal and XLHN-
affected NAVs.  ECS used in this study were individual client-owned dogs and were 
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studied because they developed juvenile-onset renal failure caused by ARHN. Diagnosis 
of ARHN in affected ECS was confirmed by electron microscopic and IF evaluations of 
their GBM. Affected ECS were euthanized at ESRD, between seven and nine months of 
age, and the renal cortex obtained. Because ECS were client-owned animals, kidneys 
from normal dogs of this breed were not available. Dogs (from several other breeds) not 
affected with AS, were also used for this study. These dogs were both client-owned and 
from an unrelated research colony and included two Dalmatians, one German Shepherd 
Dog, one Great Dane and one Havanese (Table 5.1). These dogs had no signs of renal 
disease and were euthanized for reasons unrelated to renal function. For all dogs, renal 
cortex taken at the time of necropsy was stored in RNAlater (Ambion, Austin, TX) until 
isolation of RNA.  
 
Table 5.1. Number, age and gender of dogs used to evaluate type IV collagen gene 
expression. a Age of the dogs when they were necropsied and renal cortex was obtained 
for subsequent RNA isolation.  
 
         Number       Agea (months)  Gender 
 
ARHN 
Affected English  3                                    8-12                           F(1), M(2)  
Cocker Spaniels 
 
XLHN 
Affected mixed breed             3                                    8-10                                M 
 
Dogs without HN 
Normal mixed breed  2                                    9-15        M 
Havanese   1                                    120        M 
Dalmatian   2                                    1-2        F 
German Shepherd Dog 1                                  unknown                      unknown 
Great Dane   1                                      18        M 
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RNA isolation 
Total RNA was isolated from renal cortex using RNA STAT-60 (Iso-Tex Diagnostics, 
Inc., Friendswood, TX) according to the manufacturer’s protocol. The resulting RNA 
was cleaned using the Qiagen RNeasy Mini Kit (Qiagen Inc., Valencia, CA) and the 
RNase-Free DNase Set (Qiagen Inc.), to avoid DNA contamination. RNA quality was 
assessed by one step RT-PCR with β-actin primers (Forward 5′-
TGCGTGACATTAAGGAGAAG-3′, Reverse 5′-CTGCATCCTGTCGGCAATG-3′), 
using the Sigma Enhanced Avian HS RT-PCR kit (Sigma Aldrich, St. Louis, MO). RNA 
was quantified by spectrophotometry and diluted to 1ng/ul.  
 
Real time quantitative RT-PCR 
The mRNA levels for the six type IV collagens and GAPDH (used for 
normalization) were assessed using the BioRad MyiQ Single-Color Real-Time PCR 
Detection System (BioRad Inc., Hercules, CA). Primers and probes (Table 5.2) were 
based on the published canine sequence and designed using Primer Express 1.0 (Applied 
Biosystems, Foster City, CA). When possible, probes were designed to span two exons 
to eliminate amplification of any DNA that might still be present. The 5′ and 3′ ends of 
the probes were labeled with 6-FAM (6-carboxyfluorescein) and Black Hole 
Quencher™, respectively (Biosearch Technologies, Novato, CA). Each 25µl reaction 
contained 0.2µM of each forward and reverse primer and probe, 12.5µl of 2x QuantiTect 
Probe RT-PCR Master Mix (Qiagen Inc.), 0.25µl of QuantiTect RT Mix (Qiagen Inc.) 
and 7ng of RNA.  The amplification conditions were: 50° for 30 seconds, 95° for 13 
minutes and 30 seconds followed by 45 cycles at 95° for ten seconds, 55° for 30 seconds 
 53
and 70° for 30 seconds. In order it ensure reproducibility, each sample was amplified at 
least in duplicate.  
 
 
Table 5.2. Type IV collagen primer and probe sequences. Probes are labeled with 6-
FAM on the 5′ end and BHQ-1 on the 3′ end. 
 
Gene Size (bp) Sequence 5′-3′ 
COL4A1 
 
74 
 
Forward-CCCCAAAGGACAGCAAGGT 
Reverse-CACCGTCAAAACCAGGAATACC 
Probe-CGCCACTATCGAGAGAAGCGAG 
 
COL4A2 79 Forward-TTGGCCTGGAAGGTTATCGT 
Reverse-TTCCCCTCATCTCCTTTGCTT 
Probe-AAGGGCAAACAGGCTTTCCC 
 
COL4A3 74 Forward-GAGCCTTATATTAGCAGATGCAC 
Reverse-TCAGTGGTTTGGCTGTGAATG 
Probe-TGTGAAGGTCCTACGATTGCCATAG 
 
COL4A4 70 Forward-GGCTACAGTCTGTTATACCTGAAGGA 
Reverse-AAGACCCCTGCCAGACCAA 
Probe-AGGAGAAGGCCCACAATCAGGA 
 
COL4A5 170 Forward-GAGCATGGAGCCCCTGAA 
Reverse-TCGTGTGCATCATGAAGGAATAG 
Probe-CCAGAGCATCCAGCCATTCATTAG 
 
COL4A6 62 Forward-CCAGGACCTGGGTTTTGCT 
Reverse-AGTAGATGAAGGGCATGGTGCTA 
Probe-TCCTGCCTGCCCCGCT 
 
GAPDH 67 Forward-CGGATTTGGCCGTATTGG 
Reverse-GACAATATCCACTTTGCCAGAGTTAA 
Probe-CGCCTGGTCACCAGGGC 
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Analysis 
 In order to obtain fold changes, analysis was carried out as described by Pfaffl   
assuming a PCR efficiency (E) equal to two (Pfaffl, 2001). All affected and carrier dogs 
were compared with dogs exhibiting no renal disease. Fold changes greater than two 
were considered to be indicative of changes in mRNA levels. P-values were calculated 
for each group of dogs using the bootstrap with replacement method (Efron, 1979). 
 
Results and discussion 
This study utilized qRT-PCR to analyze type IV collagen transcript levels in AS. 
Previous work by other investigators included the use of IF staining to assess protein 
expression as well as northern blotting and RNase protection assays to assess mRNA 
concentrations (Lees et al., 1998; Lees et al., 1999; Rheault et al., 2004; Zheng et al., 
2005). To complement these data, qRT-PCR, a more sensitive method for assessment of 
transcription, was performed. Data generated using this approach provide additional 
insight regarding changes in mRNA levels in the renal cortex of HN-affected subjects, 
and offer a useful comparison of these changes between two different genetic forms of 
canine HN.  
 
XLHN-affected NAV Dogs 
 To assess changes in mRNA levels in XLHN-affected NAV dogs at ESRD, 
comparisons were made to dogs, including normal NAV dogs, with no signs of renal 
disease. As shown in Figure 5.1, there was a greater than two fold reduction in COL4A5 
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mRNA levels (P=0.03) in XLHN-affected NAV dogs. No changes in mRNA levels were 
detected for COL4A3, COL4A4 and COL4A6 (P=0.65, 0.88 and 0.54, respectively).  
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Fig. 5.1. Two fold change in ratio of XLHN-affected and carrier NAV dogs and ARHN-
affected ECS compared to normal dogs. 
 
 
 
 Because the concentrations of full length transcripts of COL4A5 were reduced in 
XLHN-affected dogs, and because COL4A3, COL4A4 and COL4A6 mRNA levels in 
XLHN-affected dogs were similar to levels in normal dogs, it is tantalizing to 
hypothesize that the absence of these proteins in renal basement membranes (previously 
demonstrated by IF (Lees et al., 1999)) is due to a post-translational event. That is, 
although α3(IV), α4(IV) and α6(IV) are properly translated, the absence of functional 
α5(IV) proteins prevents the formation of the α3.α4.α5(IV) and α5.α5.α6(IV) trimers and 
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their subsequent deposition in renal basement membranes. However, further work in 
necessary to determine the correlations between mRNA and protein levels.  
 Data for the other type IV collagen genes differed from each other (Fig. 5.1). 
That is, COL4A1 exhibited no change in mRNA levels (P=0.69), whereas, COL4A2, 
exhibited a greater than a two fold decrease in mRNA levels (P=0.13). Although the P-
value obtained for COL4A2 is not strongly significant, it does support the trend of a 
decrease in mRNA levels. This is perplexing because staining for α1(IV) and α2(IV) in 
the GBM, Bowman’s capsule (BC), tubule basement membrane (TBM) and interstitium 
of XLHN-affected NAV dogs is positive (Lees et al., 1999). However, one could 
hypothesize that although there is a decrease in mRNA concentration, this is not coupled 
with an increase in the degradation of the proteins. Because there is an absence of the 
α3.α4.α5(IV) trimer in all basement membranes, the α1(IV) and α2(IV) proteins are able 
to be deposited in high enough amounts to be detected by IF staining. Therefore, a 
plausible explanation for this is that the positive staining results are due to increased 
retention of these collagens in the basement membranes, as opposed to an increase in 
their transcription or translation.   
 Although IF findings for XLHN-affected Samoyeds are similar to those for 
XLHN-affected NAV dogs (Harvey et al., 1998; Lees et al., 1999), the type IV collagen 
mRNA profiles for the Samoyed model are noticeably different from those of the NAV 
dogs. That is, the most recently published data for the Samoyed (Zheng et al., 2005) 
report an increase in both COL4A1 and COL4A2 mRNA levels, a decrease in COL4A3 
and COL4A4 mRNA levels, no detectable COL4A5 mRNA and no change in COL4A6 
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mRNA levels. With the exception of COL4A5 and COL4A6, these data differ from the 
patterns reported here for the NAV dogs. The most striking differences are shown for 
COL4A3 and COL4A4, for which no changes in mRNA levels were detected in the NAV 
dogs (Fig. 5.1). However, the findings reported herein do agree with those published for 
the murine model of XLAS (Rheault et al., 2004).  
It is important to note that the mutations leading to XLHN are different for each 
of these three models. These differences may account for the fact that the XLHN-
affected NAV dogs more closely mimic the murine XLAS model than the XLHN-
affected Samoyed dogs. Specifically, the XLHN-affected NAV dogs harbor a ten base 
pair deletion in exon nine of COL4A5, where as the XLHN-affected Samoyeds have a 
nonsense mutation in exon 35 of the same gene (Zheng et al., 1994; Cox et al., 2003). 
Therefore, the XLHN-affected NAV dogs will have an absence of much of the 
collagenous domain of the α5(IV) protein, whereas the XLHN-affected Samoyeds will 
maintain a larger portion of the collagenous domain. The XLAS murine model and the 
XLHN-affected NAV dogs are similar in both the severity of the mutation and type IV 
collagen mRNA patterns. This may be due to the fact that the mutation causative for 
XLAS in the murine model is a nonsense mutation in exon one (Rheault et al., 2004). It 
has been reported that the more severe the mutation in COL4A5, the more severe the 
disease outcome (Gross et al., 2002), which may explain the differences in transcript 
levels for these two canine models of XLHN. 
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XLHN-carrier NAV dogs 
Additionally, this work included analysis of type IV collagen transcripts of 
XLHN-carrier NAV dogs. To date, XLHN-carrier female NAV dogs have been less 
studied than their affected male counterparts. Those studies involving carriers have 
remained primarily clinical, although limited IF data are also available. In order to fully 
understand how the carrier status affects these animals it is important to evaluate their 
transcript levels. These, along with future analyses, may help to explain the clinical 
symptoms these carriers exhibit.   
Expression of COL4A5 in XLHN-carrier females is dependent on Lyonization. 
That is, due to random X-chromosome inactivation, some segments of the GBM will 
express the allele harboring the mutation, while others will express the wild type allele. 
Therefore, IF staining for α5(IV), as well as those chains that trimerize with it (i.e., 
α3(IV), α4(IV) and α6(IV)), is segmental (i.e., mosaic) in all basement membranes in 
which they normally are found (i.e., the GBM, BC and TBM) in young carrier females . 
Like their affected male counterparts, carrier female NAV dogs exhibited a 
greater than two fold decrease in COL4A5 mRNA levels (P=0.06). COL4A3 and 
COL4A6 levels were also comparable to that of the XLHN-affected dogs, that is, there 
was no change in mRNA (P=0.75 and 0.42, respectively). In direct contrast to affected 
males, carrier females showed a greater than two fold decrease in COL4A4 mRNA levels 
(P=0.03) (Fig.5.1). However, the observed relationship between COL4A4 and the 
disease may be confounded with animal age. Neither COL4A1nor COL4A2 exhibited a 
greater than two fold change in mRNA levels (P=0.08 and 0.3, respectively) (Fig. 5.1), 
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but the P-value of for COL4A1 suggests a trend of decreased mRNA levels. Although it 
is tempting to try to correlate changes in mRNA levels with IF data, this study does not 
allow for a direct comparison.   
Differences in the ages of the dogs and the stages of progression of their renal 
disease at time of necropsies certainly could contribute to the differences in mRNA 
levels observed in affected XLHN-male and XLHN-carrier female NAV dogs. The 
XLHN-carrier females were euthanized for reasons unrelated to ESRD and their ages 
varied (13 to 84 months), while XLHN-affected males were euthanized because of 
ESRD at a relatively young age (eight to ten months) (Table 5.1). 
 
ARHN-affected ECS  
The ECS samples used for this study were obtained from client owned animals, 
and this was the reason for the small samples size. Renal tissue from ARHN-affected 
ECS was difficult to obtain because the dogs must have been diagnosed before they were 
euthanized, clients had to consent to the use of their dogs for research purposes, and the 
tissues had to be shipped from various locations. The fact that these dogs are client 
owned also precluded obtaining normal tissue. This is further complicated by the fact 
that there is no genetic test to distinguish ARHN-carrier and unaffected ECS. Only 
parents of affected offspring can be definitively diagnosed as ARHN-carriers.  
 When compared to dogs without signs of renal disease (including normal NAVs), 
ARHN-affected ECS at ESRD showed a greater than two fold decrease in COL4A4 
mRNA levels, similar to the decrease in COL4A5 mRNA seen in the XLHN-affected 
 60
NAV dogs (Fig.5.1). The established P-value for COL4A4 of 0.13 is not strongly 
significant but indicates a trend of decreased mRNA levels. COL4A6 exhibited a greater 
than two fold change in its transcript levels (Fig. 5.1), however, a P-value of 0.36 was 
obtained. No provocative changes were observed for COL4A1, COL4A2, COL4A3 and 
COL4A5 (P = 0.23, 0.48, 0.49 and 0.91, respectively) (Fig. 1).  
Transcript concentrations differed in the ARHN-affected ECS from that of the 
XLHN-affected NAV dogs for COL4A1 and COL4A2. That is, the XLHN-affected NAV 
dogs showed no change in COL4A1 mRNA levels but did show a greater than two fold 
increase in COL4A2 mRNA levels (P=0.13). These differences could be due to the fact 
that these dogs have different genetic backgrounds, and more importantly that they 
exhibit two forms of HN. This could lead one to hypothesize that different pathways for 
disease progression could be utilized for the different forms of the disease.  
The IF findings for ARHN-affected ECS are similar, in some respects, to those 
for XLHN-affected NAV dogs. Specifically, there is complete absence of α3(IV) and 
α4(IV), one of which likely contains the causative mutation, in the GBM and distal 
tubule basement membrane (dTBM) (Lees et al., 1998) . Of the two genes encoding 
these proteins, COL4A4 showed a trend of decreased mRNA levels and COL4A3 showed 
no change. Therefore, this suggests that the mutation is present in COL4A4. Unlike the 
NAV dogs, ARHN-affected ECS do have widespread α5(IV) staining in their renal 
basement membranes (Lees et al., 1998; Lees et al., 1999). This is due to the fact that 
α5(IV) can trimerize with α6(IV), and in ARHN-affected ECS, these two peptides co-
localize in the BC and collecting tubule basement membranes (ctTBM), as well as to 
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some extent in the GBM. The persistence of α5(IV) in the GBM of ARHN-affected ECS 
is consistent with the normal levels of COL4A5 mRNA in these kidneys.  
Currently, there exist three murine models of ARHN, two of which are COL4A3 
NC1 domain knockouts and one of which is a COL4A3/COL4A4 transgenic insertion 
deleting the 5′ ends of both genes (Cosgrove et al., 1996; Miner and Sanes, 1996; Lu et 
al., 1999). In those models for which northern blot or IF analysis were performed, the 
gene that is mutated is absent or mRNA levels are drastically reduced, this is also the 
case for XLHN-affected NAV dogs (Cosgrove et al., 1996; Miner and Sanes, 1996; Lu 
et al., 1999). This supports our hypothesis that ARHN in the ECS is due to a mutation in 
COL4A4. However, none of the current murine models knocked out COL4A4 alone, 
which together with less quantitative forms of detection, may explain the differences 
observed in comparison of the ECS with the COL4A3 knock out murine model described 
by Miner et al. (Miner and Sanes, 1996).  These differences are minor and include the 
increase in COL4A1 mRNA levels in the murine model, whereas, there was no 
significant change in mRNA levels for either COL4A1 or COL4A2 in the ARHN-
affected ECS (Miner and Sanes, 1996).  
 This report provides a comprehensive view of type IV collagen transcript 
concentrations in two canine models of HN. This allows for comparisons between 
previously published data for other murine and canine models, and also allows a 
comparison between two forms of HN. While direct comparisons cannot currently be 
made between IF data and mRNA levels, it is important to understand how these data 
may relate to each other. Of course, further investigations should be conducted to clarify 
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this issue. This study also provides a method suitable for investigating other forms of AS 
which have not yet been characterized, such as ADHN in the Bull Terrier (Hood et al., 
1995). Finally, the data provide evidence suggesting that COL4A4 is the causative gene 
in the ECS form of ARHN. Further studies are needed to identify the causative mutation.  
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CHAPTER VI 
GENETIC CAUSE OF AUTOSOMAL RECESSIVE HEREDITARY 
NEPHROPATHY IN THE ENGLISH COCKER SPANIEL* 
Overview 
Autosomal recessive hereditary nephropathy (ARHN) in the English Cocker 
Spaniel is caused by a type IV collagen defect, but the underlying mutation is unknown. 
134 English Cocker Spaniels (12 with ARHN, eight obligate carriers and 114 others), 
three mixed breed dogs with X-linked hereditary nephropathy (XLHN) and seven other 
dogs without hereditary nephropathy were studied to determine the cause of this disease 
in the English Cocker Spaniels. Diagnosis of ARHN was based on transmission electron 
microscopy and immunostaining of kidney. Quantitative real time RT-PCR (qRT-PCR) 
was used to compare COL4A3, COL4A4 and COL4A5 mRNA levels in renal cortex from 
ARHN-affected English Cocker Spaniels, XLHN-affected dogs and dogs without HN. 
The entire coding region of COL4A4 was sequenced in two ARHN-affected dogs, two 
obligate carriers, two English Cocker Spaniels of unknown status and two normal mixed 
breed dogs. The exon containing the mutation was sequenced for all 134 English Cocker 
Spaniels. Quantitative real time RT-PCR implicated COL4A4 as the gene harboring the  
mutation, and sequencing identified a single nucleotide substitution at base 115 as the 
 
___________________ 
*Reprinted with permission from “Genetic Cause of Autosomal Recessive Hereditary 
Nephropathy in the English Cocker Spaniel” by A. Davidson, R. Bell, G. Lees, C. 
Kashtan, G. Davidson and K. Murphy, 2007. Journal of Veterinary Internal Medicine, 
21, 394-401, Copyright 2007 by American College of Veterinary Internal Medicine  
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cause of ARHN in English Cocker Spaniels. This mutation, which causes a premature  
stop codon in exon three of COL4A4, segregated with clinical status in all affected dogs 
and obligate carriers. The mutation was also identified in 39 of 114 other English Cocker 
Spaniels with previously unknown status. Now that the cause of this disease has been 
identified, use of a test for the mutation will permit eradication of ARHN in the English 
Cocker Spaniel.    
 
Introduction 
Although terms used to identify the condition have evolved over the years, an 
hereditary renal disease has been observed in the English Cocker Spaniel since the late 
1940s. Krook described a juvenile nephropathy that he termed renal cortical hypoplasia 
in 40 Cocker Spaniels that were examined at the Royal Veterinary College in Stockholm 
from 1946 to 1956 (Krook, 1957). He stated that the condition, “as a rule”, was 
characterized by “serious” albuminuria (Krook, 1957). Additional early reports about 
renal cortical hypoplasia in Cocker Spaniels from Sweden, Switzerland and Australia 
also described juvenile onset of a fatal proteinuric nephropathy (Persson et al., 1961; 
Freudiger, 1965; English and Winter, 1979). Subsequent studies demonstrated that the 
disease was inherited in an autosomal recessive fashion and that the primary renal 
lesions involved glomeruli (Steward and Macdougall, 1984; Robinson et al., 1985; 
Macdougall et al., 1987; Koeman et al., 1989). With these developments, familial 
nephropathy or “FN” became the diagnostic term most widely used for the disease. This 
term is the name by which most English Cocker Spaniel owners and breeders still know 
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the disease. However, we believe that hereditary nephropathy is the most appropriate 
diagnostic term to use for this type of primary glomerular disease in dogs. 
 Beginning in the 1980s, investigators using transmission electron microscopy 
noted that the ultrastructural appearance of the glomerular basement membranes (GBM) 
of affected dogs resembled that of human Alport syndrome (Potter et al., 1985; 
Macdougall, 1989), but that clue was of little help while the molecular and genetic basis 
of Alport syndrome remained obscure. Starting in the late 1980s, however, a series of 
discoveries established that Alport syndrome was caused by type IV collagen defects 
(Barker et al., 1990; Lemmink et al., 1994; Mochizuki et al., 1994; Hudson et al., 2003). 
Thus, when distinctive ultrastructural GBM changes were identified in an affected dog 
examined in 1992 at Texas A&M University, (Lees et al., 1997) we began systematic 
investigations of the disease based on the hypothesis that it was a type IV collagen 
disorder. Subsequent studies characterized the clinical, pathologic and ultrastructural 
features of the disease, including the evolving pattern of abnormalities observed as the 
disease progressed (Harvey et al., 1998; Lees et al., 1998). Importantly, immunostaining 
of kidney from affected dogs demonstrated complete absence of the α3(IV) and α4(IV) 
collagen peptide chains that normally are present in the GBM (Lees et al., 1998). This 
finding further suggested that the mutation responsible for the disease would affect one 
of the two genes encoding these proteins.  
Each of six type IV collagen genes encodes a distinct α chain (1-6) that can be 
assembled into three heterotrimers: α1.α1.α2(IV), α3.α4.α5(IV) and α5.α5.α6(IV) 
(Hudson et al., 2003). In adult kidney, the collagen network that provides the structural 
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framework for the GBM is composed of α3.α4.α5(IV) heterotrimers. This network is 
essential for normal GBM structure and function because renal disease, most notably 
Alport syndrome, ensues when it is absent or abnormal (Harvey et al., 1998; Hudson et 
al., 2003). Specifically, mutations in any one of the three genes encoding the α3(IV), 
α4(IV), or α5(IV) proteins can cause Alport syndrome. This occurs because a defect in 
any of the chains involved in a heterotrimer can prevent its proper assembly. The 
COL4A5 gene, which encodes the α5(IV) chain, is located on the X-chromosome in 
humans and dogs (Hudson et al., 2003; Lowe et al., 2003), and mutations in this gene 
cause human X-linked Alport syndrome and canine X-linked hereditary nephropathy 
(XLHN) (Zheng et al., 1994; Knebelmann et al., 1996; Cox et al., 2003; Hudson et al., 
2003). The COL4A3 and COL4A4 genes, encoding the α3(IV) and α4(IV) chains, 
respectively, are located on human chromosome two and canine chromosome 25 
(Hudson et al., 2003; Lowe et al., 2003). Mutations in either one of these two genes 
cause autosomal forms of Alport syndrome in humans, the same is suspected to be true 
of autosomal forms of canine hereditary nephropathy (Lemmink et al., 1994; Mochizuki 
et al., 1994; Ding et al., 1995; van der Loop et al., 2000; Longo et al., 2002; Vega et al., 
2003; Pescucci et al., 2004).  
In this report, we describe the use of quantitative real time RT-PCR (qRT-PCR) 
to identify COL4A4 as the candidate gene causative for autosomal recessive hereditary 
nephropathy (ARHN) in English Cocker Spaniels. Sequencing of COL4A4 identified a 
single base change in exon three that produces a premature stop codon. This is the first 
autosomal form of canine hereditary nephropathy in which the underlying genetic cause 
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has been identified. Appropriate use of a genetic test for this mutation will permit 
breeders of English Cocker Spaniels to eradicate the disease. 
 
Materials and methods  
Dogs and samples 
 From 1993 through 2005, ARHN was diagnosed at Texas A&M University in 18 
English Cocker Spaniels. Each diagnosis was based on finding both the characteristic 
ultrastructural GBM changes by transmission electron microscopy and the distinctively 
abnormal pattern of type IV collagen expression in renal basement membranes by 
immunostaining, as previously described (Lees et al., 1998). Diagnosis of ARHN in 
individual dogs identified specific families in which the disease trait was inherited, so 
family histories were collected. Parents of affected dogs were presumed to be obligate 
heterozygous carriers of the disease trait. Whenever possible, genomic DNA was 
obtained from affected dogs, each of their parents and as many closely related dogs as 
were available. Additionally, DNA samples were collected from some English Cocker 
Spaniels that were not known to be related to any dog in which ARHN had been 
diagnosed. A commercially available kit, Gentra Puregene DNA Isolation Kit (Gentra 
Systems, Minneapolis, MN), was used to isolate DNA from nucleated cells in whole 
blood or buccal swab specimens, according to the manufacturer’s instructions. 
Renal specimens suitable for RNA isolation also were obtained at necropsy from 
13 dogs (Table 6.1). The three English Cocker Spaniels with ARHN were among the 18 
dogs mentioned previously, and the three mixed breed dogs with XLHN were from 
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kindred maintained in a colony at Texas A&M University. The dogs with XLHN harbor 
a ten base pair deletion in COL4A5 (Cox et al., 2003). Status of dogs in the kindred with 
XLHN was determined by genotype of this mutation with the following primers: 
Forward 5′-CGCTTGACTATTTTGTGTGTCATAA-3′, Reverse 5′-
AAGGTGATGCTGTGATCTGATTTA-3′. The seven dogs without hereditary 
nephropathy that were studied included two unaffected dogs from the XLHN kindred.  
 
 
Table 6.1. Number, age and gender of dogs used to evaluate type IV collagen gene 
expression in samples of renal cortex.  
a Age of the dogs when they were necropsied and renal cortex was obtained for 
subsequent RNA isolation.  
 
         Number       Agea (months)  Gender 
 
ARHN 
Affected English  3                                    8-12                           F(1), M(2)  
Cocker Spaniels 
 
XLHN 
Affected mixed breed             3                                    8-10                                M 
 
Dogs without HN 
Normal mixed breed  2                                    9-15        M 
Havanese   1                                    120        M 
Dalmatian   2                                    1-2        F 
German Shepherd Dog 1                                  unknown                      unknown 
Great Dane   1                                      18        M 
 
 
 
 
However, all of the English Cocker Spaniels that we studied were client-owned, and 
samples of renal cortex from unaffected dogs of this breed were not available. 
Consequently, we used renal cortical specimens that were available from five dogs of 
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other breeds. These dogs were both client-owned and from an unrelated research colony 
and included two Dalmatians, one German Shepherd Dog, one Great Dane and one 
Havanese. These dogs had no evidence of renal disease and were euthanized for reasons 
unrelated to renal function. All renal cortex samples obtained at necropsy were stored in 
RNAlater (Ambion Inc, Austin, TX), an RNA stabilization solution, until isolation of 
RNA using a RNA STAT-60 following the manufacturers protocol (Iso-Tex Diagnostics 
Inc, Friendswood, TX). 
Additionally, during 2005 and 2006, formalin-fixed specimens of kidney from 
English Cocker Spaniels with juvenile-onset renal failure were received from Great 
Britain (one dog) and Sweden (one dog). Before shipment to Texas A&M University, 
the tissue samples were processed and embedded for routine light microscopic and 
transmission electron microscopic evaluations. Upon receipt, the embedded tissues were 
sectioned, stained and examined by standard methods, as previously described (Lees et 
al., 1998). Family histories were also collected for these dogs, together with DNA 
specimens from closely related dogs. Again, the Gentra Puregene DNA Isolation Kit 
(Gentra Systems), a commercially available kit, was used to isolate DNA from nucleated 
cells in whole blood or buccal swab specimens, according to the manufacturer’s 
instructions.  
 
Quantitative real time RT-PCR 
 Levels of mRNA transcripts for COL4A3, COL4A4, COL4A5 and GAPDH (used 
for normalization) in renal cortex were quantified using the BioRad MyiQ Single-Color 
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Real-Time PCR Detection System (BioRad Inc, Hercules, CA). Primers and probes 
(Table 6.2) were designed with Primer Expression 1.0 (Applied Biosystems, Foster City, 
CA) based on the published canine sequence. The probe designed for each of COL4A3, 
COL4A4 and COL4A5 were designed to span two exons to eliminate the detection of any 
DNA that might still be present. The 5′ and 3′ ends of the probes were labeled with 6-
FAM (6-carboxyfluorescein) and Black Hole Quencher™ (Biosearch Technologies, 
Novato, CA), respectively. Each 25µl reaction contained 0.2µM of each forward and 
reverse primer and probe, 12.5µl of 2x QuantiTect Probe RT-PCR Master Mix (Qiagen 
Inc., Valencia, CA), 0.25µl of QuantiTect RT Mix (Qiagen Inc.) and 7ng of RNA.  The  
 
 
Table 6.2. Primer and probe sequences for quantitative real time RT-PCR.  
 
Name                 Size (bp)                Sequence 5′-3′ 
 
COL4A3                 74                     Forward-GAGCCTTATATTAGCAGATGCAC 
                                                         Reverse-TCAGTGGTTTGGCTGTGAATG 
                                                         Probe-TGTGAAGGTCCTACGATTGCCATAG 
 
COL4A4                 70                     Forward-GGCTACAGTCTGTTATACCTGAAGGA 
                                                         Reverse-AAGACCCCTGCCAGACCAA 
                                                         Probe-AGGAGAAGGCCCACAATCAGGA 
 
COL4A5                170                    Forward-GAGCATGGAGCCCCTGAA 
                                                         Reverse-TCGTGTGCATCATGAAGGAATAG 
                                                         Probe-CCAGAGCATCCAGCCATTCATTAG 
 
 
 
amplification conditions were: 50° for 30 seconds, 95° for 13 minutes and 30 seconds 
followed by 45 cycles at 95° for 10 seconds, 55° for 30 seconds and 70° for 30 seconds. 
In order to ensure reproducibility, each dog was amplified in at least duplicate. More 
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specifically, each dog for GAPDH was amplified five times, COL4A3 and COL4A5 three 
times and COL4A4 five times.  
Results were analyzed by comparing ARHN-affected and XLHN-affected dogs 
with the dogs that did not have hereditary nephropathy. Fold changes were obtained as 
described by Pfaffl (Pfaffl, 2001), and fold changes greater than two were considered to 
be indicative of differences in mRNA levels. P-values were calculated for each 
comparison (i.e., ARHN-affected vs. unaffected and XLAS-affected vs. unaffected) 
using the bootstrap with replacement method (Efron, 1979).  This method is performed 
by resampling with replacement 100 times from the collection of measured values, while 
honoring the null hypothesis (i.e., that there is no difference between groups' mean 
responses). P-values are then estimated by the fraction of bootstrap values that exceed 
the actual observed differences, and thus could have been by random chance alone.  
 
Sequencing of COL4A4 
    The canine COL4A4 gene contains 47 exons, and the entire coding region was 
sequenced and analyzed. Most of the coding region (41 exons) was analyzed by 
amplifying and sequencing individual exons together with their flanking intronic 
regions. However, three pairs of exons (10 and 11, 13 and 14, and 38 and 39) were 
sequenced together because of the short length of their intervening introns. Thus, a total 
of (44) sets of primers were designed to amplify portions of COL4A4 using the 
published canine genome sequence (Table 6.3). Intron/exon boundaries were determined 
by aligning the canine genome sequence in the region on chromosome 25 around 
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COL4A4 and the previously published mRNA sequence for COL4A4 (accession No. 
AY263363). 
 Amplification by PCR was carried out with each reaction containing 50ng of 
DNA, 2mM of MgCl, .25mM of each dNTP, 1.0µM of each primer (forward and 
reverse), 5% DMSO, 0.001mg of Bovine Serum Albumin (Promega, Madison, WI), 0.75 
units of Taq DNA Polymerase (Fisher Scientific, Pittsburgh, PA), and 1µl of  1X Taq 
DNA Polymerase Buffer B (Fisher Scientific). Amplification cycling conditions were as 
follows: 94°C for 5 minutes, followed by 35 cycles of 94°C for 30 seconds, 55° - 58°C 
for 30 seconds and 72°C for 30 seconds, then a single cycle at 72°C for 10 minutes. 
Products were separated by gel electrophoresis and then visualized using ethidium 
bromide. When multiple amplification products were present, the desired amplicon was 
purified using the Qiaex II Gel Extraction Kit (Qiagen Inc.), a commercially available 
kit. If only the desired amplicon was present, 7µl of the product was purified using ten 
units of Exonuclease I (Epicentre, Madison, WI) and 1 unit of Shrimp Alkaline 
Phosphatase (Roche, Indianapolis, IN) and incubated at 37°C for 30 minutes and 
followed by a 15 minute incubation at 80°C. Purified products were then used for 
nucleotide sequencing using the Big Dye Terminator v 1.1 Cycle Sequencing Kit 
(Applied Biosystems) and resolved on an ABI 3730 Genetic Analyzer (Applied 
Biosystems).  
  To identify the mutation, sequence was obtained from two affected dogs, two 
obligate carriers, two English Cocker Spaniels of unknown genetic status and two 
normal mixed breed dogs. Sequences were aligned using Clustal W 
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(http://www.ebi.ac.uk/clustalw/) and nucleotide polymorphisms that segregated with 
ARHN in English Cocker Spaniels were identified. To verify the mutation, exon three 
was amplified and sequenced in every affected English Cocker Spaniel and obligate 
carrier from which an adequate DNA sample was available. 
Once the causative mutation was identified, exon three was amplified and 
sequenced in 114 additional English Cocker Spaniels having unknown genetic status. 
This was accomplished using the same primers for exon three (Table 6.3) and nucleotide 
sequencing procedure as has already been described. 
 
Results 
Quantitative real time RT-PCR 
 To assess gene expression changes in XLHN-affected dogs and ARHN-affected 
English Cocker Spaniels, comparisons were made with dogs having no evidence of renal 
disease. There was a greater than two-fold reduction in COL4A5 mRNA (P=0.03) in 
XLHN-affected dogs (Fig 6.1), but no changes in mRNA levels for COL4A3 or COL4A4 
(P =0.65 and 0.88, respectively) were detected. English Cocker Spaniels with ARHN 
had a greater than two-fold reduction in COL4A4 mRNA levels, similar to that seen for 
COL4A5 in XLHN-affected dogs; however, the P-value for this reduction (P=0.13) was 
not significant. No provocative changes in mRNA levels were observed for COL4A3 or 
COL4A5 (P =0.49 and 0.91, respectively) (Fig 6.1). This pattern of findings for the 
English Cocker Spaniels with ARHN suggested that underlying mutation was more 
likely to be in COL4A4 than in COL4A3, so we proceeded with sequencing of that gene.  
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Sequencing of COL4A4 
Regions of COL4A4 were sequenced from genomic DNA obtained from a total 
of 134 English Cocker Spaniels. These included 12 affected dogs, eight obligate carriers 
and 89 other dogs from the United States and Canada, as well as 19 dogs from Great 
Britain and six dogs from Sweden.   
 To identify the causative mutation, COL4A4 was sequenced and analyzed for two 
ARHN-affected dogs and two obligate carriers. The sequence obtained was compared to 
that obtained from two English Cocker Spaniels of unknown status and two normal 
 
 
Fig. 6.1. Results of quantitative real time RT-PCR analysis of the expression of selected 
type IV collagen genes in the renal cortex of XLHN-affected mixed breed dogs and 
ARHN-affected English Cocker Spaniels. Each bar shows the fold change in the 
designated group of affected dogs compared with the group of dogs without HN for the 
indicated gene. White bars represent XLHN-affected mixed breed dogs, black bars 
represent ARHN-affected English Cocker Spaniels. 
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mixed breed dogs, as well as to the published canine coding sequence for COL4A4 
(accession AY2633363) and the published 7X NIH genomic reference sequence for the 
dog. This analysis revealed a single nucleotide substitution (adenine changed to 
thymine) at base 115, causing a nonsense mutation (lysine changed to a stop codon) in 
exon three of both affected dogs (Figs 6.2 and 6.3). Additionally, each of the two carriers 
had both an adenine and a thymine (i.e., an adenine from the normal allele and a thymine 
from the mutated allele) at base 115 (Fig 6.2 and 6.3).  
 
 
 
 
 
 
 
 
 
 
Fig. 6.2. Chromatographs showing DNA sequence results for COL4A4 in English 
Cocker Spaniels (ECS). Top panel, a normal dog; middle panel, an obligate carrier of 
ARHN; and bottom panel, an ARHN-affected dog. The affected dog is homozygous and 
the carrier is heterozygous for the mutated allele (thymine instead of adenine) in exon 
three. Base at which mutation occurs is marked by an asterisk in each panel.  
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To verify the mutation, exon three of COL4A4 was sequenced using genomic 
DNA from 12 English Cocker Spaniels with ARHN, as well as from eight obligate 
carriers. In every instance in which an affected or obligate carrier dog’s DNA was 
sequenced and analyzed, the same mutation was identified (i.e., homozygous in the 
affected dogs and heterozygous in the carriers). 
Sequence analysis of COL4A4 also revealed two single nucleotide 
polymorphisms (SNPs) that co-segregated with the disease. Both SNPs are in the intron 
upstream of exon 42. The first, which is a thymine to adenine substitution, is located 93 
bases upstream. The second, which is a thymine to cytosine substitution, is 90 bases 
upstream. These two nucleotide changes do not alter the coding sequence of the gene, 
but they are inherited with the disease trait.  
Exon three of COL4A4 was also sequenced using genomic DNA from 114 
English Cocker Spaniels having unknown genetic status. These dogs included 65 that 
were close relatives of obligate carriers (i.e., parents, siblings, or offspring) in which the 
random odds of finding the dog to be heterozygous for the mutation were one in two 
(i.e., 50% chance of also being a carrier). Among these 65 dogs, 34 (52.3%) were 
heterozygous for the mutation and were thus also identified as carriers. Among the 
remaining 44 dogs, in which the chances of being a carrier were ≤ 25%, only 3 (6.8%) 
were heterozygous for the mutation. Five dogs (two of which were identified as carriers) 
could not be placed into the above categories due to the absence of relationship 
information or a conclusive diagnosis. Therefore, a total of 39 previously unknown 
carriers were identified. 
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Light microscopic examination of stained sections of formalin-fixed, paraffin-
embedded kidney from the English Cocker Spaniel in Sweden that died of juvenile-onset 
renal failure was sufficient to exclude ARHN as the cause of that dog’s renal disease. 
The histologic lesions were unmistakably those of renal dysplasia. Samples of DNA 
were available from the affected dog, both of its parents and three other closely related 
dogs. Tests for the mutated COL4A4 allele that causes ARHN were negative in these six 
dogs. 
 Results of the pathologic evaluations of kidney from the English Cocker Spaniel 
from Great Britain that was suspected to have ARHN were inconclusive. The light 
microscopic and transmission electron microscopic findings were compatible with the 
disease, but they were not sufficiently distinctive to permit definitive diagnosis. 
Glomerular ultrastructure was too poorly preserved in the available formalin-fixed tissue 
for critical evaluation, and the material was not suitable for immunostaining. However, 
DNA specimens were available from six related dogs, including the dog’s sire. Genetic 
testing demonstrated that the sire was heterozygous for the mutated COL4A4 allele and 
that the other five dogs were homozygous for the normal allele. 
Overall, the sequence data we obtained for exon three of COL4A4 in English 
Cocker Spaniels identified the genetic status of a total of 134 dogs from the United 
States, Canada, Great Britain and Sweden. With 12 affected dogs and 47 carriers in this 
sample, the overall frequency of the mutated allele in the English Cocker Spaniels that 
we studied was 0.2649 (71 of 268). However, this sample included at least four separate 
kindreds, and in two small kindreds (containing 19 and six dogs) in which an affected 
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dog had not been diagnosed, the frequencies of the mutated allele were 0.0263 (one of 
38) and zero (none of 12), respectively. However, this frequency may not be accurate for 
the ECS population as a whole because only four kindred were studied. 
 
 
 
 
Fig. 6.3. Diagram of the COL4A4 mutation that causes ARHN in the English Cocker 
Spaniel. The top panel is a schematic representation of genomic COL4A4, indicating all 
47 exons and the intervening introns in approximate scale. The middle panel represents 
an enlargement of the portion of the top panel that includes exons two, three and four. 
The bottom panel shows a portion of the nucleotide and translated amino acid sequences 
within exon three (base 106 – 157) for normal dogs and for affected dogs. The A-T 
transversion at base 115 (marked by the asterisk) creates a premature stop codon in the 
affected dog sequence.  
 
 
   
Discussion 
 Hereditary nephropathy is caused by mutations in any one of the three genes 
encoding the type IV collagens found in the GBM. Specifically, XLHN is caused by 
5’ 3’
5’ 3’
Exon 2 Exon 3 Exon 4
* 
Normal 
S     G      K     K     F    V     G      F     V    G      P      C     G    G    R     D     C    
AGTGGAAAGAAGTTTGTCGGCCCCTGTGGAGGAAGAGATTGCTCGGTGTGC 
AGTGGAAAGTAGTTTGTCGGCCCCTGTGGAGGAAGAGATTGCTCGGTGTGC 
S     G      K     * 
Affected 
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mutations in COL4A5 and mutations in either COL4A3 or COL4A4 can be causative for 
ARHN. Results of our qRT-PCR analysis of mRNA transcript levels for these genes in 
the renal cortex of affected dogs showed that in the XLHN-affected dogs, COL4A5, the 
gene harboring their causative mutation, had a greater then two-fold reduction. However, 
COL4A3 and COL4A4 showed no change in mRNA levels. In ARHN-affected English 
Cocker Spaniels, mRNA levels for COL4A4, but not for COL4A3 or COL4A5, also were 
reduced greater than two-fold. Based on the observation that the only reduction in 
mRNA levels for XLHN-affected dogs was in the gene harboring the mutation, and that 
ARHN-affected English Cocker Spaniels had a reduction in only one of the three 
transcripts as well, we hypothesized that the cause of ARHN in English Cocker Spaniels 
was most likely a COL4A4 defect. We then succeeded in identifying the causative 
mutation by sequencing that gene.  
Predictable consequences of the missense mutation we identified in exon three of 
COL4A4 explain all of the salient features of ARHN in affected English Cocker 
Spaniels. The mechanism by which mutations causing HN lead to the previously 
discussed changes in mRNA levels for their respective genes is uncertain, but nonsense-
mediated decay is a potential explanation (Baker and Parker, 2004). Another feature of 
ARHN in affected English Cocker Spaniels is that immunostaining demonstrates total 
absence of α4(IV) chains and α3(IV) chains in GBM, together with greatly reduced 
GBM α5(IV) chain expression (Lees et al., 1998). Because the mutation creates a 
premature stop codon, any protein synthesis directed by the mutated gene would 
generate a severely truncated peptide that would be unable to combine with its normal 
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partners (i.e., α3(IV) and α5(IV) chains) to produce stable α3.α4.α5(IV) heterotrimers. 
Without the ability to form α3.α4.α5(IV) heterotrimers, the only collagen networks that 
can form in renal basement membranes of English Cocker Spaniels with ARHN are 
composed of α1.α1.α2(IV) or α5.α5.α6(IV) heterotrimers, or both. This accounts for the 
observation that all renal basement membranes in English Cocker Spaniels with ARHN 
that exhibit α5(IV) chain expression by immunostaining also exhibit co-expression of 
α6(IV) chains, but renal expression of both α3(IV) chains and α4(IV) chains is totally 
absent even where α5(IV) chains are expressed (Lees et al., 1998). Finally, absence of 
the α3.α4.α5(IV) network in the GBM of affected dogs accounts for all of the 
ultrastructural, clinical and pathologic features of the progressive nephropathy that 
occurs in English Cocker Spaniels with ARHN. The nephropathy that develops in these 
dogs has essentially the same ultrastructural, clinical and pathologic features as the 
nephropathy that occurs in dogs with XLHN in which the α3.α4.α5(IV) network is 
missing from the GBM because of a COL4A5 mutation (Jansen et al., 1986; Jansen et al., 
1987; Thorner et al., 1987; Harvey et al., 1998; Lees et al., 1999). 
We expect that the mutation causing ARHN in English Cocker Spaniels will be 
identical by descent within this breed worldwide. To date, however, the only nations 
from which we have had opportunities to test dogs that were found to carry the mutated 
allele are the United States, Canada and Great Britain. Assessment of the distribution 
and frequency of the mutated allele among English Cocker Spaniels worldwide will 
require further studies.  
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The fact that ARHN has persisted in the English Cocker Spaniel breed for more 
than 50 years is a testament to the difficulties that have previously existed in identifying 
carriers of the mutated allele. In the past, carriers have been accurately identified only 
when a mating produced at least one affected dog that was properly diagnosed. Thus, 
although astute breeders commonly managed to avoid producing affected dogs, the 
mutated allele readily persisted in the gene pool and unsuspected carriers eventually 
were mated to one another from time to time. Availability of a test for the mutated 
COL4A4 allele should solve these problems.  
In English Cocker Spaniels with renal disease, a test for the mutated COL4A4 
allele will be useful only in those dogs with clinical and light microscopic findings that 
are compatible with a diagnosis of ARHN. Therefore, even in a young English Cocker 
Spaniel with renal disease, testing for the mutated allele should be done in conjuction 
with a thorough clinical and pathologic investigation of the dog’s illness. First, a genetic 
diagnosis of ARHN should be assessed for its ability to adequately explain the dog’s 
clinical and pathologic findings. Additionally and even more importantly, absent an 
appropriate clinical and pathologic investigation, a genetic test that excludes ARHN 
provides no information about what disease actually caused the nephropathy.  
These concepts are illustrated by our evaluations of the specimens in this study 
from the English Cocker Spaniels in Great Britain and Sweden. The clinical and 
pathologic features of the dog from Great Britain were consistent with ARHN, but the 
condition could not be definitively diagnosed using the formalin-fixed tissues that were 
available for examination. In this setting, results of the genetic test permitted us to 
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resolve our uncertainty about the correct diagnosis. Conversely, pathologic features of 
the nephropathy in the dog from Sweden were sufficient to exclude ARHN as its cause 
and tests for the mutated allele were negative. The final diagnosis, however, was based 
on clinical and histopathological evaluations.  
A test for the mutated COL4A4 allele may have some utility as an aid in the 
diagnosis of ARHN in English Cocker Spaniels with renal disease, but it will be of 
greatest value in guiding future selective breeding of these dogs. Indeed, proper use of a 
test to detect the mutated allele should permit breeders of English Cocker Spaniels to 
eradicate ARHN from this breed in as short a time as one generation and without having 
to abandon any breeding lines that have other desirable traits. This can be accomplished 
by testing all dogs in the breeding population to ensure that matings of two carriers are 
avoided so that no more dogs will develop renal failure due to ARHN. Testing of 
progeny from matings that include one carrier can be used for selection of future 
breeding stock to completely eliminate the mutate allele from the English Cocker 
Spaniel gene pool within the foreseeable future.  
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CHAPTER VII 
CONCLUDING REMARKS 
 
 The work reported herein describes research conducted using a canine model of 
human AS. By using the dog as a model, a better understanding of this disease in the 
human can be obtained. However, this research will also directly benefit the dog. This 
work is a result of the effort of many participants with the goal of better understanding 
HN in the dog and AS in the human. 
 As a continuation of the discovery of the mutation causative for XLHN in the 
NAV dogs, Chapter II describes the development of a genomic test to accurately 
genotype these dogs. It was only through the publication of the canine genome that this 
goal was accomplished. This genomic test allows dogs to be genotyped with speed and 
accuracy never before available. Early knowledge of the genotype also allows for better 
planning for future experiments.  
 The importance of studying XLHN-affected NAV males is clear but it is also, 
critical to study the female carriers of this disease.  The original idea for this research 
was to use the XLHN-carrier NAV females to study the effect X-chromosome 
inactivation patterns have on disease progression. However, in the course of our studies, 
it was determined that most XLHN-carrier females have very similar patterns of 
unskewed XCI. Although these dogs are not suitable for a long-term study to correlate 
disease progression with XCI, XCI patterns found in renal tissue do accurately reflect 
those found in blood. This provides further evidence that invasive biopsies are not 
necessarily needed to study XCI in this disease, peripheral blood will suffice. 
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 Currently, there are no treatments available to substantially prolong the lives of 
AS or HN patients without dialysis or transplantation. Therefore, in an effort to help in 
the development of a gene transfer therapy, a synthetic canine COL4A5 cDNA was 
constructed. In the future, this gene will be introduced in to affected kidneys in an 
attempt to repair the GBM. Proof that this type of therapy is possible would ideally lead 
to the development of a similar treatment for humans. 
Quantitative real time RT-PCR was used to analyze type IV collagen gene 
expression patterns of XLAS-affected NAV dogs and ARHN-affected ECS. The primary 
objective of this work was to identify the gene harboring the mutation causative for 
ARHN in the ECS.  By comparing patterns of mRNA expression of these dogs, it was 
hypothesized that COL4A4 harbored a mutation that is causative for ARHN in the ECS.  
 Data from the quantitative real time RT-PCR experiment indicated that COL4A4 
should be sequenced. Sequencing revealed a nonsense mutation in COL4A4 of exon 
three in affected dogs. This mutation causes a severely truncated protein. The 
identification of this mutation has allowed a test to be developed that allows owners of 
ECS to identify dogs that are carriers. Prior to this test, the only way to positively 
identify carriers of this disease was by the production of affected offspring. Now, 
breeders can arrange to mate carriers only with normal dogs and, in this way, keep the 
desired traits of the breed while avoiding the production of affected pups.  
 In conclusion, this work provides more insight into HN in the domestic dog 
while also moving towards the goal of a gene transfer treatment for humans affected by 
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AS. Identification of the mutation causative for ARHN in the ECS is the finding 
necessary for elimination this disease from the breed. 
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